<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35563107</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>MicroRNA Alteration, Application as Biomarkers, and Therapeutic Approaches in Neurodegenerative Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4718</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23094718</ELocationID><Abstract><AbstractText>MicroRNAs (miRNAs) are essential post-transcriptional gene regulators involved in various neuronal and non-neuronal cell functions and play a key role in pathological conditions. Numerous studies have demonstrated that miRNAs are dysregulated in major neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, or Huntington's disease. Hence, in the present work, we constructed a comprehensive overview of individual microRNA alterations in various models of the above neurodegenerative diseases. We also provided evidence of miRNAs as promising biomarkers for prognostic and diagnostic approaches. In addition, we summarized data from the literature about miRNA-based therapeutic applications via inhibiting or promoting miRNA expression. We finally identified the overlapping miRNA signature across the diseases, including miR-128, miR-140-5p, miR-206, miR-326, and miR-155, associated with multiple etiological cellular mechanisms. However, it remains to be established whether and to what extent miRNA-based therapies could be safely exploited in the future as effective symptomatic or disease-modifying approaches in the different human neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>T P Nhung</ForeName><Initials>TPN</Initials><Identifier Source="ORCID">0000-0001-9506-7838</Identifier><AffiliationInfo><Affiliation>Pharmacology and Toxicology Unit, Department of Pharmacy, University of Genoa, Viale Cembrano 4, 16148 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Mandeep</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmacology and Toxicology Unit, Department of Pharmacy, University of Genoa, Viale Cembrano 4, 16148 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fedele</LastName><ForeName>Ernesto</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0386-0925</Identifier><AffiliationInfo><Affiliation>Pharmacology and Toxicology Unit, Department of Pharmacy, University of Genoa, Viale Cembrano 4, 16148 Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonanno</LastName><ForeName>Giambattista</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3744-5786</Identifier><AffiliationInfo><Affiliation>Pharmacology and Toxicology Unit, Department of Pharmacy, University of Genoa, Viale Cembrano 4, 16148 Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonifacino</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3966-9874</Identifier><AffiliationInfo><Affiliation>Pharmacology and Toxicology Unit, Department of Pharmacy, University of Genoa, Viale Cembrano 4, 16148 Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inter-University Center for the Promotion of the 3Rs Principles in Teaching &amp; Research (Centro 3R), 56122 Genoa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2018.AAI629.U730/SD/pv</GrantID><Agency>Compagnia di San Paolo</Agency><Country/></Grant><Grant><GrantID>2017F2A2C5-002</GrantID><Agency>Ministry of Education, Universities and Research</Agency><Country/></Grant><Grant><GrantID>April16/848-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C546087">MIRN206 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545322">MIRN326 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C544302">Mirn140 microRNA, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="Y">Huntington Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease (AD)</Keyword><Keyword MajorTopicYN="N">Huntington&#x2019;s disease (HD)</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease (PD)</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">dysregulation</Keyword><Keyword MajorTopicYN="N">microRNAs (miRNAs)</Keyword><Keyword MajorTopicYN="N">multiple sclerosis (MS)</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>14</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35563107</ArticleId><ArticleId IdType="pmc">PMC9104163</ArticleId><ArticleId IdType="doi">10.3390/ijms23094718</ArticleId><ArticleId IdType="pii">ijms23094718</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anglicheau D., Muthukumar T., Suthanthiran M. MicroRNAs: Small RNAs With Big Effects. Transplantation. 2010;90:105&#x2013;112. doi: 10.1097/TP.0b013e3181e913c2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0b013e3181e913c2</ArticleId><ArticleId IdType="pmc">PMC3094098</ArticleId><ArticleId IdType="pubmed">20574417</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien J., Hayder H., Zayed Y., Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol. 2018;9:402. doi: 10.3389/fendo.2018.00402.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2018.00402</ArticleId><ArticleId IdType="pmc">PMC6085463</ArticleId><ArticleId IdType="pubmed">30123182</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva C., Esteves M., Bernardino L. MicroRNA: Basic concepts and implications for regeneration and repair of neurodegenerative diseases. Biochem. Pharmacol. 2017;141:118&#x2013;131. doi: 10.1016/j.bcp.2017.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2017.07.008</ArticleId><ArticleId IdType="pubmed">28709951</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswambharan V., Thanseem I., Vasu M.M., Poovathinal S.A., Anitha A. miRNAs as biomarkers of neurodegenerative disorders. Biomark. Med. 2017;11:151&#x2013;167. doi: 10.2217/bmm-2016-0242.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2016-0242</ArticleId><ArticleId IdType="pubmed">28125293</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S., V&#xe1;zquez L.A.B., Uribe S.P., Reyes-P&#xe9;rez P.R., Sharma A. Current Status of microRNA-Based Therapeutic Approaches in Neurodegenerative Disorders. Cells. 2020;9:1698. doi: 10.3390/cells9071698.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9071698</ArticleId><ArticleId IdType="pmc">PMC7407981</ArticleId><ArticleId IdType="pubmed">32679881</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843&#x2013;854. doi: 10.1016/0092-8674(93)90529-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90529-Y</ArticleId><ArticleId IdType="pubmed">8252621</ArticleId></ArticleIdList></Reference><Reference><Citation>Wightman B., Ha I., Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993;75:855&#x2013;862. doi: 10.1016/0092-8674(93)90530-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90530-4</ArticleId><ArticleId IdType="pubmed">8252622</ArticleId></ArticleIdList></Reference><Reference><Citation>Catanesi M., D&#x2019;Angelo M., Tupone M.G., Benedetti E., Giordano A., Castelli V., Cimini A. MicroRNAs Dysregulation and Mitochondrial Dysfunction in Neurodegenerative Diseases. Int. J. Mol. Sci. 2020;21:5986. doi: 10.3390/ijms21175986.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21175986</ArticleId><ArticleId IdType="pmc">PMC7504116</ArticleId><ArticleId IdType="pubmed">32825273</ArticleId></ArticleIdList></Reference><Reference><Citation>Faller M., Toso D., Matsunaga M., Atanasov I., Senturia R., Chen Y., Zhou Z.H., Guo F. DGCR8 recognizes primary transcripts of microRNAs through highly cooperative binding and formation of higher-order structures. RNA. 2010;16:1570&#x2013;1583. doi: 10.1261/rna.2111310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.2111310</ArticleId><ArticleId IdType="pmc">PMC2905756</ArticleId><ArticleId IdType="pubmed">20558544</ArticleId></ArticleIdList></Reference><Reference><Citation>Proshkina E., Solovev I., Koval L., Moskalev A. The critical impacts of small RNA biogenesis proteins on aging, longevity and age-related diseases. Ageing Res. Rev. 2020;62:101087. doi: 10.1016/j.arr.2020.101087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2020.101087</ArticleId><ArticleId IdType="pubmed">32497728</ArticleId></ArticleIdList></Reference><Reference><Citation>Brites D. Regulatory function of microRNAs in microglia. Glia. 2020;68:1631&#x2013;1642. doi: 10.1002/glia.23846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23846</ArticleId><ArticleId IdType="pubmed">32463968</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukhari S.I., Truesdell S.S., Lee S., Kollu S., Classon A., Boukhali M., Jain E., Mortensen R.D., Yanagiya A., Sadreyev R.I., et al. A Specialized Mechanism of Translation Mediated by FXR1a-Associated MicroRNP in Cellular Quiescence. Mol. Cell. 2016;61:760&#x2013;773. doi: 10.1016/j.molcel.2016.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2016.02.013</ArticleId><ArticleId IdType="pmc">PMC4811377</ArticleId><ArticleId IdType="pubmed">26942679</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang J.-Y., Kaneko N., Noh K.-M., Pontarelli F., Zukin R.S. The Gene Silencing Transcription Factor REST Represses miR-132 Expression in Hippocampal Neurons Destined to Die. J. Mol. Biol. 2014;426:3454&#x2013;3466. doi: 10.1016/j.jmb.2014.07.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2014.07.032</ArticleId><ArticleId IdType="pmc">PMC4373704</ArticleId><ArticleId IdType="pubmed">25108103</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Inoue K., Ishii J., Vanti W.B., Voronov S.V., Murchison E., Hannon G., Abeliovich A. A MicroRNA Feedback Circuit in Midbrain Dopamine Neurons. Science. 2007;317:1220&#x2013;1224. doi: 10.1126/science.1140481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1140481</ArticleId><ArticleId IdType="pmc">PMC2782470</ArticleId><ArticleId IdType="pubmed">17761882</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., He Q., Chen Y., Shao W., Yuan C., Wang Y. JNK-mediated microglial DICER degradation potentiates inflammatory responses to induce dopaminergic neuron loss. J. Neuroinflamm. 2018;15:184. doi: 10.1186/s12974-018-1218-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1218-1</ArticleId><ArticleId IdType="pmc">PMC6003208</ArticleId><ArticleId IdType="pubmed">29907159</ArticleId></ArticleIdList></Reference><Reference><Citation>Emde A., Eitan C., Liou L., Libby R.T., Rivkin N., Magen I., Reichenstein I., Oppenheim H., Eilam R., Silvestroni A., et al. Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: A new mechanism for ALS. EMBO J. 2015;34:2633&#x2013;2651. doi: 10.15252/embj.201490493.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201490493</ArticleId><ArticleId IdType="pmc">PMC4641530</ArticleId><ArticleId IdType="pubmed">26330466</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y., Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc. Natl. Acad. Sci. USA. 2012;109:3347&#x2013;3352. doi: 10.1073/pnas.1112427109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1112427109</ArticleId><ArticleId IdType="pmc">PMC3295278</ArticleId><ArticleId IdType="pubmed">22323604</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association Alzheimer&#x2019;s Disease Facts and Figures. Alzheimer Dement. 2020;16:391&#x2013;460. doi: 10.1002/ALZ.12068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ALZ.12068</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi P.N., Srivastava P., Sharma P., Tripathi M.K., Seth A., Tripathi A., Rai S.N., Singh S., Shrivastava S.K. Biphenyl-3-oxo-1,2,4-triazine linked piperazine derivatives as potential cholinesterase inhibitors with anti-oxidant property to improve the learning and memory. Bioorganic Chem. 2018;85:82&#x2013;96. doi: 10.1016/j.bioorg.2018.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioorg.2018.12.017</ArticleId><ArticleId IdType="pubmed">30605887</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava P., Tripathi P.N., Sharma P., Rai S.N., Singh S., Srivastava R.K., Shankar S., Shrivastava S.K. Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory. Eur. J. Med. Chem. 2018;163:116&#x2013;135. doi: 10.1016/j.ejmech.2018.11.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2018.11.049</ArticleId><ArticleId IdType="pubmed">30503937</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A.K., Rai S.N., Maurya A., Mishra G., Awasthi R., Shakya A., Chellappan D.K., Dua K., Vamanu E., Chaudhary S.K., et al. Therapeutic Potential of Phytoconstituents in Management of Alzheimer&#x2019;s Disease. Evid.-Based Complementary Altern. Med. 2021;2021:5578574. doi: 10.1155/2021/5578574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/5578574</ArticleId><ArticleId IdType="pmc">PMC8208882</ArticleId><ArticleId IdType="pubmed">34211570</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumurgier J., Tzourio C. Epidemiology of neurological diseases in older adults. Rev. Neurol. 2020;176:642&#x2013;648. doi: 10.1016/j.neurol.2020.01.356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2020.01.356</ArticleId><ArticleId IdType="pubmed">32145981</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabr&#xf2; M., Rinaldi C., Santoro G., Crisafulli C. The biological pathways of Alzheimer disease: A review. AIMS Neurosci. 2021;8:86&#x2013;132. doi: 10.3934/Neuroscience.2021005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/Neuroscience.2021005</ArticleId><ArticleId IdType="pmc">PMC7815481</ArticleId><ArticleId IdType="pubmed">33490374</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K., Liu F., Gong C.-X. Tau and neurodegenerative disease: The story so far. Nat. Rev. Neurol. 2016;12:15&#x2013;27. doi: 10.1038/nrneurol.2015.225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.225</ArticleId><ArticleId IdType="pubmed">26635213</ArticleId></ArticleIdList></Reference><Reference><Citation>Dansokho C., Heneka M.T. Neuroinflammatory responses in Alzheimer&#x2019;s disease. J. Neural Transm. 2018;125:771&#x2013;779. doi: 10.1007/s00702-017-1831-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-017-1831-7</ArticleId><ArticleId IdType="pubmed">29273951</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf6;nnies E., Trushina E. Oxidative Stress, Synaptic Dysfunction, and Alzheimer&#x2019;s Disease. J. Alzheimers Dis. 2017;57:1105&#x2013;1121. doi: 10.3233/JAD-161088.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-161088</ArticleId><ArticleId IdType="pmc">PMC5409043</ArticleId><ArticleId IdType="pubmed">28059794</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T., Zhang D., Zeng Y., Huang T.Y., Xu H., Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer&#x2019;s disease. Mol. Neurodegener. 2020;15:40. doi: 10.1186/s13024-020-00391-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00391-7</ArticleId><ArticleId IdType="pmc">PMC7364557</ArticleId><ArticleId IdType="pubmed">32677986</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Jaber V., Alexandrov P.N., Vergallo A., Lista S., Hampel H., Lukiw W.J. microRNA-Based Biomarkers in Alzheimer&#x2019;s Disease (AD) Front. Neurosci. 2020;14:585432. doi: 10.3389/fnins.2020.585432.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.585432</ArticleId><ArticleId IdType="pmc">PMC7664832</ArticleId><ArticleId IdType="pubmed">33192270</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedlecki-Wullich D., Mi&#xf1;ano-Molina A.J., Rodr&#xed;guez-&#xc1;lvarez J. microRNAs as Early Biomarkers of Alzheimer&#x2019;s Disease: A Synaptic Perspective. Cells. 2021;10:113. doi: 10.3390/cells10010113.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10010113</ArticleId><ArticleId IdType="pmc">PMC7827653</ArticleId><ArticleId IdType="pubmed">33435363</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F., Chen H., Jia Y., Lu H., Tan Q., Zhou X. miR-149-5p inhibition reduces Alzheimer&#x2019;s disease &#x3b2;-amyloid generation in 293/APPsw cells by upregulating H4K16ac via KAT8. Exp. Ther. Med. 2020;20:88. doi: 10.3892/etm.2020.9216.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2020.9216</ArticleId><ArticleId IdType="pmc">PMC7507054</ArticleId><ArticleId IdType="pubmed">32973937</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiribuzi R., Crispoltoni L., Porcellati S., Di Lullo M., Florenzano F., Pirro M., Bagaglia F., Kawarai T., Zampolini M., Orlacchio A., et al. miR128 up-regulation correlates with impaired amyloid &#x3b2;(1-42) degradation in monocytes from patients with sporadic Alzheimer&#x2019;s disease. Neurobiol. Aging. 2014;35:345&#x2013;356. doi: 10.1016/j.neurobiolaging.2013.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.08.003</ArticleId><ArticleId IdType="pubmed">24064186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W., Noh H., Lee Y., Jeon J., Shanmugavadivu A., McPHIE D.L., Kim K.-S., Cohen B.M., Seo H., Sonntag K.C. MiR-126 Regulates Growth Factor Activities and Vulnerability to Toxic Insult in Neurons. Mol. Neurobiol. 2016;53:95&#x2013;108. doi: 10.1007/s12035-014-8989-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8989-x</ArticleId><ArticleId IdType="pmc">PMC4437970</ArticleId><ArticleId IdType="pubmed">25407931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kou X., Chen D., Chen N. The Regulation of microRNAs in Alzheimer&#x2019;s Disease. Front. Neurol. 2020;11:288. doi: 10.3389/fneur.2020.00288.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00288</ArticleId><ArticleId IdType="pmc">PMC7180504</ArticleId><ArticleId IdType="pubmed">32362867</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel N., Hoang D., Miller N., Ansaloni S., Huang Q., Rogers J.T., Lee J.C., Saunders A.J. MicroRNAs can regulate human APP levels. Mol. Neurodegener. 2008;3:10. doi: 10.1186/1750-1326-3-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-3-10</ArticleId><ArticleId IdType="pmc">PMC2529281</ArticleId><ArticleId IdType="pubmed">18684319</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang M., Wang J., Zhang X., Geng Y., Hu Z., Rudd J.A., Ling S., Chen W., Han S. The miR-124 regulates the expression of BACE1/&#x3b2;-secretase correlated with cell death in Alzheimer&#x2019;s disease. Toxicol. Lett. 2012;209:94&#x2013;105. doi: 10.1016/j.toxlet.2011.11.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxlet.2011.11.032</ArticleId><ArticleId IdType="pubmed">22178568</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W.-X., Rajeev B.W., Stromberg A.J., Ren N., Tang G., Huang Q., Rigoutsos I., Nelson P.T. The Expression of MicroRNA miR-107 Decreases Early in Alzheimer&#x2019;s Disease and May Accelerate Disease Progression through Regulation of &#x3b2;-Site Amyloid Precursor Protein-Cleaving Enzyme 1. J. Neurosci. 2008;28:1213&#x2013;1223. doi: 10.1523/JNEUROSCI.5065-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5065-07.2008</ArticleId><ArticleId IdType="pmc">PMC2837363</ArticleId><ArticleId IdType="pubmed">18234899</ArticleId></ArticleIdList></Reference><Reference><Citation>Boissonneault V., Plante I., Rivest S., Provost P. MicroRNA-298 and MicroRNA-328 Regulate Expression of Mouse &#x3b2;-Amyloid Precursor Protein-converting Enzyme 1. J. Biol. Chem. 2009;284:1971&#x2013;1981. doi: 10.1074/jbc.M807530200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M807530200</ArticleId><ArticleId IdType="pmc">PMC2908704</ArticleId><ArticleId IdType="pubmed">18986979</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Liu C., Zhu J., Shu P., Yin B., Gong Y., Qiang B., Yuan J., Peng X. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer&#x2019;s-associated pathogenesis in SAMP8 mice. Neurobiol. Aging. 2012;33:522&#x2013;534. doi: 10.1016/j.neurobiolaging.2010.04.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.04.034</ArticleId><ArticleId IdType="pubmed">20619502</ArticleId></ArticleIdList></Reference><Reference><Citation>Estfanous S., Daily K.P., Eltobgy M., Deems N.P., Anne M.N.K., Krause K., Badr A., Hamilton K., Carafice C., Hegazi A., et al. Elevated Expression of MiR-17 in Microglia of Alzheimer&#x2019;s Disease Patients Abrogates Autophagy-Mediated Amyloid-&#x3b2; Degradation. Front. Immunol. 2021;12:705581. doi: 10.3389/fimmu.2021.705581.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.705581</ArticleId><ArticleId IdType="pmc">PMC8379081</ArticleId><ArticleId IdType="pubmed">34426734</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H.-C., Wang L.-M., Wang M., Song B., Tan S., Teng J.-F., Duan D.-X. MicroRNA-195 downregulates Alzheimer&#x2019;s disease amyloid-&#x3b2; production by targeting BACE1. Brain Res. Bull. 2012;88:596&#x2013;601. doi: 10.1016/j.brainresbull.2012.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2012.05.018</ArticleId><ArticleId IdType="pubmed">22721728</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong G., An F., Wang Y., Bian M., Yu L.-J., Wei C. miR-15b represses BACE1 expression in sporadic Alzheimer&#x2019;s disease. Oncotarget. 2017;8:91551&#x2013;91557. doi: 10.18632/oncotarget.21177.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.21177</ArticleId><ArticleId IdType="pmc">PMC5710945</ArticleId><ArticleId IdType="pubmed">29207665</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu J., Xiong X., Hujie G., Ren J., Yan L., Ma L. MicroRNA-132-3p alleviates neuron apoptosis and impairments of learning and memory abilities in Alzheimer&#x2019;s disease by downregulation of HNRNPU stabilized BACE1. Cell Cycle. 2021;20:2309&#x2013;2320. doi: 10.1080/15384101.2021.1982507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2021.1982507</ArticleId><ArticleId IdType="pmc">PMC8794521</ArticleId><ArticleId IdType="pubmed">34585626</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Xu Y., Wang B., Huang J., Li Q. miR-34a-5p and miR-125b-5p attenuate A&#x3b2;-induced neurotoxicity through targeting BACE1. J. Neurol. Sci. 2020;413:116793. doi: 10.1016/j.jns.2020.116793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.116793</ArticleId><ArticleId IdType="pubmed">32251872</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y., Tu Q., Liu M. MicroRNA-125b regulates Alzheimer&#x2019;s disease through SphK1 regulation. Mol. Med. Rep. 2018;18:2373&#x2013;2380. doi: 10.3892/mmr.2018.9156.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2018.9156</ArticleId><ArticleId IdType="pubmed">29901156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X., Liu L., Meng J. MicroRNA-125b promotes neurons cell apoptosis and Tau phosphorylation in Alzheimer&#x2019;s disease. Neurosci. Lett. 2017;661:57&#x2013;62. doi: 10.1016/j.neulet.2017.09.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.09.043</ArticleId><ArticleId IdType="pubmed">28947385</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabry R., El Sharkawy R.E., Gad N.M. MiRNA-483-5p as a Potential Noninvasive Biomarker for Early Detection of Alzheimer&#x2019;s Disease. Egypt. J. Immunol. 2020;27:59&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">33548978</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y., Yan H., Teng Y., Wang Q., Yang P., Zhang L., Cheng H., Fu S. Long non-coding RNA 00507/miRNA-181c-5p/TTBK1/MAPT axis regulates tau hyperphosphorylation in Alzheimer&#x2019;s disease. J. Gene Med. 2020;22:e3268. doi: 10.1002/jgm.3268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgm.3268</ArticleId><ArticleId IdType="pubmed">32891070</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu T., Shu Y., Qu Y., Gao S., Zhang L. miR-26b inhibits total neurite outgrowth, promotes cells apoptosis and downregulates neprilysin in Alzheimer&#x2019;s disease. Int. J. Clin. Exp. Pathol. 2018;11:3383&#x2013;3390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6962878</ArticleId><ArticleId IdType="pubmed">31949715</ArticleId></ArticleIdList></Reference><Reference><Citation>Song D., Li G., Hong Y., Zhang P., Zhu J., Yang L., Huang J. miR-199a decreases Neuritin expression involved in the development of Alzheimer&#x2019;s disease in APP/PS1 mice. Int. J. Mol. Med. 2020;46:384&#x2013;396. doi: 10.3892/ijmm.2020.4602.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2020.4602</ArticleId><ArticleId IdType="pmc">PMC7255456</ArticleId><ArticleId IdType="pubmed">32626916</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Zhao J., Lu G. miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer&#x2019;s disease. Biochem. Biophys. Res. Commun. 2016;478:852&#x2013;857. doi: 10.1016/j.bbrc.2016.08.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.08.037</ArticleId><ArticleId IdType="pubmed">27520374</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert S.S., Papadopoulou A.S., Smith P., Galas M.-C., Planel E., Silahtaroglu A.N., Sergeant N., Bu&#xe9;e L., De Strooper B. Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum. Mol. Genet. 2010;19:3959&#x2013;3969. doi: 10.1093/hmg/ddq311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq311</ArticleId><ArticleId IdType="pubmed">20660113</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezache L., Mikhail M., Garofalo M., Nuovo G.J. Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons with Hyperphosphorylated Tau Protein in Alzheimer Disease. Appl. Immunohistochem. Mol. Morphol. 2015;23:615&#x2013;623. doi: 10.1097/PAI.0000000000000147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PAI.0000000000000147</ArticleId><ArticleId IdType="pubmed">26258756</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Veremeyko T., Wong A.H.-K., EL Fatimy R., Wei Z., Cai W., Krichevsky A.M., Wang Y., Veremeyko T., Wong A.H.-K., et al. Downregulation of miR-132/212 impairs S-nitrosylation balance and induces tau phosphorylation in Alzheimer&#x2019;s disease. Neurobiol. Aging. 2017;51:156&#x2013;166. doi: 10.1016/j.neurobiolaging.2016.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.12.015</ArticleId><ArticleId IdType="pubmed">28089352</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Ortiz C.J., Prieto G.A., Martini A.C., Forner S., Trujillo-Estrada L., LaFerla F.M., Baglietto-Vargas D., Cotman C.W., Kitazawa M. miR-181a negatively modulates synaptic plasticity in hippocampal cultures and its inhibition rescues memory deficits in a mouse model of Alzheimer&#x2019;s disease. Aging Cell. 2020;19:e13118. doi: 10.1111/acel.13118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13118</ArticleId><ArticleId IdType="pmc">PMC7059142</ArticleId><ArticleId IdType="pubmed">32087004</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva M.M., Rodrigues B., Fernandes J., Santos S.D., Carreto L., Santos M.A.S., Pinheiro P., Carvalho A.L. MicroRNA-186-5p controls GluA2 surface expression and synaptic scaling in hippocampal neurons. Proc. Natl. Acad. Sci. USA. 2019;116:5727&#x2013;5736. doi: 10.1073/pnas.1900338116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1900338116</ArticleId><ArticleId IdType="pmc">PMC6431224</ArticleId><ArticleId IdType="pubmed">30808806</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Yoon H., Chung D.-E., Brown J.L., Belmonte K.C., Kim J. miR-186 is decreased in aged brain and suppresses BACE1 expression. J. Neurochem. 2016;137:436&#x2013;445. doi: 10.1111/jnc.13507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13507</ArticleId><ArticleId IdType="pmc">PMC4837067</ArticleId><ArticleId IdType="pubmed">26710318</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S., Jun S., Rellick S., Quintana D., Cavendish J., Simpkins J. Expression of microRNA-34a in Alzheimer&#x2019;s disease brain targets genes linked to synaptic plasticity, energy metabolism, and resting state network activity. Brain Res. 2016;1646:139&#x2013;151. doi: 10.1016/j.brainres.2016.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.05.026</ArticleId><ArticleId IdType="pmc">PMC4975975</ArticleId><ArticleId IdType="pubmed">27235866</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L., Li H., Liu W., Zhang L., Tian Q., Li H., Li M. MiR-485-3p serves as a biomarker and therapeutic target of Alzheimer&#x2019;s disease via regulating neuronal cell viability and neuroinflammation by targeting AKT3. Mol. Genet. Genom. Med. 2021;9:e1548. doi: 10.1002/mgg3.1548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mgg3.1548</ArticleId><ArticleId IdType="pmc">PMC7963426</ArticleId><ArticleId IdType="pubmed">33220166</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D., Zhao D., Zhao Y., Wang Y., Zhao Y., Wen C. Inhibition of microRNA-155 Alleviates Cognitive Impairment in Alzheimer&#x2019;s Disease and Involvement of Neuroinflammation. Curr. Alzheimer Res. 2019;16:473&#x2013;482. doi: 10.2174/1567205016666190503145207.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205016666190503145207</ArticleId><ArticleId IdType="pubmed">31456514</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Zhang J., Sun X., Ma G., Luo G., Miao Z., Song L. miR-132 improves the cognitive function of rats with Alzheimer&#x2019;s disease by inhibiting the MAPK1 signal pathway. Exp. Ther. Med. 2020;20:159. doi: 10.3892/etm.2020.9288.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2020.9288</ArticleId><ArticleId IdType="pmc">PMC7571341</ArticleId><ArticleId IdType="pubmed">33093897</ArticleId></ArticleIdList></Reference><Reference><Citation>Han C., Guo L., Yang Y., Guan Q., Shen H., Sheng Y., Jiao Q. Mechanism of microRNA-22 in regulating neuroinflammation in Alzheimer&#x2019;s disease. Brain Behav. 2020;10:e01627. doi: 10.1002/brb3.1627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.1627</ArticleId><ArticleId IdType="pmc">PMC7303389</ArticleId><ArticleId IdType="pubmed">32307887</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Lei C. Neuroprotective effects of miR-331-3p through improved cell viability and inflammatory marker expression: Correlation of serum miR-331-3p levels with diagnosis and severity of Alzheimer&#x2019;s disease. Exp. Gerontol. 2021;144:111187. doi: 10.1016/j.exger.2020.111187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2020.111187</ArticleId><ArticleId IdType="pubmed">33279668</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Fang Y., Zhao X., Zheng Y., Ma Y., Li S., Huang Z., Li L. miR-204 silencing reduces mitochondrial autophagy and ROS production in a murine AD model via the TRPML1-activated STAT3 pathway. Mol. Ther.-Nucleic Acids. 2021;24:822&#x2013;831. doi: 10.1016/j.omtn.2021.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2021.02.010</ArticleId><ArticleId IdType="pmc">PMC8121631</ArticleId><ArticleId IdType="pubmed">34026326</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M.-L., Hong C.-G., Yue T., Li H.-M., Duan R., Hu W.-B., Cao J., Wang Z.-X., Chen C.-Y., Hu X.-K., et al. Inhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer&#x2019;s disease by enhancing autophagy. Theranostics. 2021;11:2395&#x2013;2409. doi: 10.7150/thno.47408.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.47408</ArticleId><ArticleId IdType="pmc">PMC7797673</ArticleId><ArticleId IdType="pubmed">33500732</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahangard Y., Monfared H., Moradi A., Zare M., Mirnajafi-Zadeh J., Mowla S.J. Therapeutic Effects of Transplanted Exosomes Containing miR-29b to a Rat Model of Alzheimer&#x2019;s Disease. Front. Neurosci. 2020;14:564. doi: 10.3389/fnins.2020.00564.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00564</ArticleId><ArticleId IdType="pmc">PMC7314926</ArticleId><ArticleId IdType="pubmed">32625049</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong Y., Yu P., Cheng H., Wang H., Wang X., Liang C., Zhu H., Qin Y., Qin C. miR-29c regulates NAV3 protein expression in a transgenic mouse model of Alzheimer&#x2019;s disease. Brain Res. 2015;1624:95&#x2013;102. doi: 10.1016/j.brainres.2015.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2015.07.022</ArticleId><ArticleId IdType="pubmed">26212654</ArticleId></ArticleIdList></Reference><Reference><Citation>Jash K., Gondaliya P., Sunkaria A., Kalia K. MicroRNA-29b Modulates &#x3b2;-Secretase Activity in SH-SY5Y Cell Line and Diabetic Mouse Brain. Cell. Mol. Neurobiol. 2020;40:1367&#x2013;1381. doi: 10.1007/s10571-020-00823-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-020-00823-4</ArticleId><ArticleId IdType="pubmed">32198621</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong Y., Wang H., Dong W., Quan X., Zhu H., Xu Y., Huang L., Ma C., Qin C. miR-29c regulates BACE1 protein expression. Brain Res. 2011;1395:108&#x2013;115. doi: 10.1016/j.brainres.2011.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.04.035</ArticleId><ArticleId IdType="pubmed">21565331</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Wu L., Hu Y., Jiang L., Liang N., Chen J., Qin H., Tang N. MicroRNA-107 Ameliorates Damage in a Cell Model of Alzheimer&#x2019;s Disease by Mediating the FGF7/FGFR2/PI3K/Akt Pathway. J. Mol. Neurosci. 2020;70:1589&#x2013;1597. doi: 10.1007/s12031-020-01600-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-020-01600-0</ArticleId><ArticleId IdType="pubmed">32472396</ArticleId></ArticleIdList></Reference><Reference><Citation>Moncini S., Lunghi M., Valmadre A., Grasso M., Del Vescovo V., Riva P., Denti M.A., Venturin M. The miR-15/107 Family of microRNA Genes Regulates CDK5R1/p35 with Implications for Alzheimer&#x2019;s Disease Pathogenesis. Mol. Neurobiol. 2017;54:4329&#x2013;4342. doi: 10.1007/s12035-016-0002-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0002-4</ArticleId><ArticleId IdType="pubmed">27343180</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng C., Meng X., Mai D., Xu K., Qu S. Overexpression of miR-132-3p contributes to neuronal protection in in vitro and in vivo models of Alzheimer&#x2019;s disease. Behav. Brain Res. 2022;417:113584. doi: 10.1016/j.bbr.2021.113584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2021.113584</ArticleId><ArticleId IdType="pubmed">34536429</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaraj S., Want A., Laskowska-Kaszub K., Fesiuk A., Vaz S., Logarinho E., Wojda U. Candidate Alzheimer&#x2019;s Disease Biomarker miR-483-5p Lowers TAU Phosphorylation by Direct ERK1/2 Repression. Int. J. Mol. Sci. 2021;22:3653. doi: 10.3390/ijms22073653.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22073653</ArticleId><ArticleId IdType="pmc">PMC8037306</ArticleId><ArticleId IdType="pubmed">33915734</ArticleId></ArticleIdList></Reference><Reference><Citation>Cos&#xed;n-Tom&#xe0;s M., Antonell A., Llad&#xf3; A., Alcolea D., Fortea J., Ezquerra M., Lle&#xf3; A., Mart&#xed; M.J., Pall&#xe0;s M., Sanchez-Valle R., et al. Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer&#x2019;s Disease: Potential and Limitations. Mol. Neurobiol. 2017;54:5550&#x2013;5562. doi: 10.1007/s12035-016-0088-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0088-8</ArticleId><ArticleId IdType="pubmed">27631879</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson J.R., Kruse C., Montagna D.R., Finsen B., Wolfe M.S. Alternative polyadenylation and miR-34 family members regulate tau expression. J. Neurochem. 2013;127:739&#x2013;749. doi: 10.1111/jnc.12437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12437</ArticleId><ArticleId IdType="pmc">PMC3859707</ArticleId><ArticleId IdType="pubmed">24032460</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Chen P., Wang X., Yao J., Zhuang S. miR-34a deficiency in APP/PS1 mice promotes cognitive function by increasing synaptic plasticity via AMPA and NMDA receptors. Neurosci. Lett. 2018;670:94&#x2013;104. doi: 10.1016/j.neulet.2018.01.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2018.01.045</ArticleId><ArticleId IdType="pubmed">29378298</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanach C., Blusztajn J., Fischer A., Delalle I. MicroRNAs as Candidate Biomarkers for Alzheimer&#x2019;s Disease. Non-Coding RNA. 2021;7:8. doi: 10.3390/ncrna7010008.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ncrna7010008</ArticleId><ArticleId IdType="pmc">PMC7930943</ArticleId><ArticleId IdType="pubmed">33535543</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbagallo C., Mostile G., Baglieri G., Giunta F., Luca A., Raciti L., Zappia M., Purrello M., Ragusa M., Nicoletti A. Specific Signatures of Serum miRNAs as Potential Biomarkers to Discriminate Clinically Similar Neurodegenerative and Vascular-Related Diseases. Cell. Mol. Neurobiol. 2020;40:531&#x2013;546. doi: 10.1007/s10571-019-00751-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-019-00751-y</ArticleId><ArticleId IdType="pubmed">31691877</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara N., Kikuchi M., Miyashita A., Hatsuta H., Saito Y., Kasuga K., Murayama S., Ikeuchi T., Kuwano R. Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer&#x2019;s disease. Acta Neuropathol. Commun. 2017;5:10. doi: 10.1186/s40478-017-0414-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0414-z</ArticleId><ArticleId IdType="pmc">PMC5282710</ArticleId><ArticleId IdType="pubmed">28137310</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q.S., Cai D. Integrated miRNA-Seq and mRNA-Seq Study to Identify miRNAs Associated with Alzheimer&#x2019;s Disease Using Post-mortem Brain Tissue Samples. Front. Neurosci. 2021;15:620899. doi: 10.3389/fnins.2021.620899.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.620899</ArticleId><ArticleId IdType="pmc">PMC8021900</ArticleId><ArticleId IdType="pubmed">33833661</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Z., Gu H., Guo Q., Liang S., Xue J., Yao F., Liu X., Li F., Liu H., Sun L., et al. Profiling of Serum Exosome MiRNA Reveals the Potential of a MiRNA Panel as Diagnostic Biomarker for Alzheimer&#x2019;s Disease. Mol. Neurobiol. 2021;58:3084&#x2013;3094. doi: 10.1007/s12035-021-02323-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02323-y</ArticleId><ArticleId IdType="pubmed">33629272</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha D.J., Mengel D., Mustapic M., Liu W., Selkoe D.J., Kapogiannis D., Galasko D., Rissman R.A., Bennett D.A., Walsh D.M. miR-212 and miR-132 Are Downregulated in Neurally Derived Plasma Exosomes of Alzheimer&#x2019;s Patients. Front. Neurosci. 2019;13:1208. doi: 10.3389/fnins.2019.01208.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01208</ArticleId><ArticleId IdType="pmc">PMC6902042</ArticleId><ArticleId IdType="pubmed">31849573</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain G., Stuendl A., Rao P., Berulava T., Centeno T.P., Kaurani L., Burkhardt S., Delalle I., Kornhuber J., H&#xfc;ll M., et al. A combined miRNA&#x2013;piRNA signature to detect Alzheimer&#x2019;s disease. Transl. Psychiatry. 2019;9:1208. doi: 10.1038/s41398-019-0579-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-019-0579-2</ArticleId><ArticleId IdType="pmc">PMC6779890</ArticleId><ArticleId IdType="pubmed">31591382</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansari A., Maffioletti E., Milanesi E., Marizzoni M., Frisoni G.B., Blin O., Richardson J.C., Bordet R., Forloni G., Gennarelli M., et al. miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer&#x2019;s disease. Neurobiol. Aging. 2019;82:102&#x2013;109. doi: 10.1016/j.neurobiolaging.2019.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.06.005</ArticleId><ArticleId IdType="pubmed">31437718</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokavec M., Li H., Jiang L., Hermeking H. The p53/miR-34 axis in development and disease. J. Mol. Cell Biol. 2014;6:214&#x2013;230. doi: 10.1093/jmcb/mju003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mju003</ArticleId><ArticleId IdType="pubmed">24815299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou T., Zhou Y., Zhu L., Wang X., Pang P., Wang D., Liuyang Z., Man H., Lu Y., Liu D. Correcting abnormalities in miR-124/PTPN1 signaling rescues tau pathology in Alzheimer&#x2019;s disease. J. Neurochem. 2020;154:441&#x2013;457. doi: 10.1111/jnc.14961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14961</ArticleId><ArticleId IdType="pubmed">31951013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B.K., Kim M.H., Lee S.Y., Son S.J., Hong C.H., Jung Y.-S. Downregulated Platelet miR-1233-5p in Patients with Alzheimer&#x2019;s Pathologic Change with Mild Cognitive Impairment is Associated with A&#x3b2;-Induced Platelet Activation via P-Selectin. J. Clin. Med. 2020;9:1642. doi: 10.3390/jcm9061642.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9061642</ArticleId><ArticleId IdType="pmc">PMC7357133</ArticleId><ArticleId IdType="pubmed">32485903</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros-Viegas A.T., Carmona V., Ferreiro E., Guedes J., Cardoso A., Cunha P.P., de Almeida L.P., de Oliveira C.R., de Magalh&#xe3;es J.P., Pe&#xe7;a J. miRNA-31 Improves Cognition and Abolishes Amyloid-&#x3b2; Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimer&#x2019;s Disease. Mol. Ther.-Nucleic Acids. 2020;19:1219&#x2013;1236. doi: 10.1016/j.omtn.2020.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2020.01.010</ArticleId><ArticleId IdType="pmc">PMC7031139</ArticleId><ArticleId IdType="pubmed">32069773</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G.-D., Li Z.-H., Li X., Zheng T., Zhang D.-K. microRNA-592 blockade inhibits oxidative stress injury in Alzheimer&#x2019;s disease astrocytes via the KIAA0319-mediated Keap1/Nrf2/ARE signaling pathway. Exp. Neurol. 2020;324:113128. doi: 10.1016/j.expneurol.2019.113128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2019.113128</ArticleId><ArticleId IdType="pubmed">31759899</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao W., Yu L., Shu S., Liu Y., Zhuang Z., Xu S., Bao X., Gu Y., Cai F., Song W., et al. miR-204-3p/Nox4 Mediates Memory Deficits in a Mouse Model of Alzheimer&#x2019;s Disease. Mol. Ther. 2010;29:396&#x2013;408. doi: 10.1016/j.ymthe.2020.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.09.006</ArticleId><ArticleId IdType="pmc">PMC7791017</ArticleId><ArticleId IdType="pubmed">32950103</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabr M.T., Brogi S. MicroRNA-Based Multitarget Approach for Alzheimer&#x2019;s Disease: Discovery of the First-In-Class Dual Inhibitor of Acetylcholinesterase and MicroRNA-15b Biogenesis. J. Med. Chem. 2020;63:9695&#x2013;9704. doi: 10.1021/acs.jmedchem.0c00756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c00756</ArticleId><ArticleId IdType="pubmed">32787143</ArticleId></ArticleIdList></Reference><Reference><Citation>Balestrino R., Schapira A.H.V. Parkinson disease. Eur. J. Neurol. 2020;27:27&#x2013;42. doi: 10.1111/ene.14108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14108</ArticleId><ArticleId IdType="pubmed">31631455</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallett P.J., Engelender S., Isacson O. Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson&#x2019;s disease. J. Neuroinflamm. 2019;16:153. doi: 10.1186/s12974-019-1532-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1532-2</ArticleId><ArticleId IdType="pmc">PMC6647317</ArticleId><ArticleId IdType="pubmed">31331333</ArticleId></ArticleIdList></Reference><Reference><Citation>Gigu&#xe8;re N., Nanni S.B., Trudeau L.-E. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson&#x2019;s Disease. Front. Neurol. 2018;9:455. doi: 10.3389/fneur.2018.00455.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00455</ArticleId><ArticleId IdType="pmc">PMC6018545</ArticleId><ArticleId IdType="pubmed">29971039</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong M.J., Okun M.S. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323:548&#x2013;560. doi: 10.1001/jama.2019.22360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.22360</ArticleId><ArticleId IdType="pubmed">32044947</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich S.G., Savitt J.M. Parkinson&#x2019;s Disease. Med. Clin. N. Am. 2019;103:337&#x2013;350. doi: 10.1016/j.mcna.2018.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcna.2018.10.014</ArticleId><ArticleId IdType="pubmed">30704685</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacabelos R. Parkinson&#x2019;s Disease: From Pathogenesis to Pharmacogenomics. Int. J. Mol. Sci. 2017;18:551. doi: 10.3390/ijms18030551.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18030551</ArticleId><ArticleId IdType="pmc">PMC5372567</ArticleId><ArticleId IdType="pubmed">28273839</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Jiang Y., Wang Y., Yang S., Bi X., Pan X., Ma A. MiR-181b regulates autophagy in a model of Parkinson&#x2019;s disease by targeting the PTEN/Akt/mTOR signaling pathway. Neurosci. Lett. 2018;675:83&#x2013;88. doi: 10.1016/j.neulet.2018.03.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2018.03.041</ArticleId><ArticleId IdType="pubmed">29608948</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Q., Zhong Z., Hu B., Yan S., Yan Y., Zhang J., Shi T., Jiang L., Li W., Huang W. MicroRNA-3473b regulates the expression of TREM2/ULK1 and inhibits autophagy in inflammatory pathogenesis of Parkinson disease. J. Neurochem. 2021;157:599&#x2013;610. doi: 10.1111/jnc.15299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15299</ArticleId><ArticleId IdType="pubmed">33448372</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y., Xiong J., Ji L., Xue X. MiR-421 Aggravates Neurotoxicity and Promotes Cell Death in Parkinson&#x2019;s Disease Models by Directly Targeting MEF2D. Neurochem. Res. 2021;46:299&#x2013;308. doi: 10.1007/s11064-020-03166-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-020-03166-0</ArticleId><ArticleId IdType="pubmed">33179210</ArticleId></ArticleIdList></Reference><Reference><Citation>Prajapati P., Sripada L., Singh K., Roy M., Bhatelia K., Dalwadi P., Singh R. Systemic Analysis of miRNAs in PD Stress Condition: miR-5701 Modulates Mitochondrial&#x2013;Lysosomal Cross Talk to Regulate Neuronal Death. Mol. Neurobiol. 2018;55:4689&#x2013;4701. doi: 10.1007/s12035-017-0664-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0664-6</ArticleId><ArticleId IdType="pubmed">28710704</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng R., Luo D.-X., Li H.-P., Zhang Q.-S., Lei S.-S., Chen J.-H. MicroRNA-135b alleviates MPP+-mediated Parkinson&#x2019;s disease in in vitro model through suppressing FoxO1-induced NLRP3 inflammasome and pyroptosis. J. Clin. Neurosci. 2019;65:125&#x2013;133. doi: 10.1016/j.jocn.2019.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2019.04.004</ArticleId><ArticleId IdType="pubmed">31036506</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Deng M.-F., Xiong W., Xie A.-J., Guo J., Liang Z.-H., Hu B., Chen J.-G., Zhu X., Man H., et al. MicroRNA-26a/Death-Associated Protein Kinase 1 Signaling Induces Synucleinopathy and Dopaminergic Neuron Degeneration in Parkinson&#x2019;s Disease. Biol. Psychiatry. 2019;85:769&#x2013;781. doi: 10.1016/j.biopsych.2018.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2018.12.008</ArticleId><ArticleId IdType="pmc">PMC8861874</ArticleId><ArticleId IdType="pubmed">30718039</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y.-B., Zhang Y.-F., Wang H., Ren R.-J., Cui H.-L., Huang W.-Y., Cheng Q., Chen H.-Z., Wang G. miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson&#x2019;s disease. Cell Death Dis. 2019;10:589. doi: 10.1038/s41419-019-1809-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1809-5</ArticleId><ArticleId IdType="pmc">PMC6683159</ArticleId><ArticleId IdType="pubmed">31383850</ArticleId></ArticleIdList></Reference><Reference><Citation>Khodr C.E., Becerra A., Han Y., Bohn M.C. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: Positive and negative effects. Brain Res. 2014;1550:47&#x2013;60. doi: 10.1016/j.brainres.2014.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2014.01.010</ArticleId><ArticleId IdType="pmc">PMC3974902</ArticleId><ArticleId IdType="pubmed">24463035</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Sun L., Jia K., Wang H., Wang X. miR-9-5p modulates the progression of Parkinson&#x2019;s disease by targeting SIRT. Neurosci. Lett. 2019;701:226&#x2013;233. doi: 10.1016/j.neulet.2019.02.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2019.02.038</ArticleId><ArticleId IdType="pubmed">30826419</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C., Zhu J., Yuan J., Xiang Y., Dai L. Pramipexole Inhibits MPP+-Induced Neurotoxicity by miR-494-3p/BDNF. Neurochem. Res. 2020;45:268&#x2013;277. doi: 10.1007/s11064-019-02910-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-019-02910-5</ArticleId><ArticleId IdType="pubmed">31811458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Meng X., Tan F., Jiao Z., Zhang X., Tong H., He X., Luo X., Xu P., Qu S. Regulatory Mechanism of miR-543-3p on GLT-1 in a Mouse Model of Parkinson&#x2019;s Disease. ACS Chem. Neurosci. 2019;10:1791&#x2013;1800. doi: 10.1021/acschemneuro.8b00683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.8b00683</ArticleId><ArticleId IdType="pubmed">30676715</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Li Q., He Y., Yang Y., Ma Q., Li C. miR-29c-3p inhibits microglial NLRP3 inflammasome activation by targeting NFAT5 in Parkinson&#x2019;s disease. Genes Cells. 2020;25:364&#x2013;374. doi: 10.1111/gtc.12764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/gtc.12764</ArticleId><ArticleId IdType="pubmed">32160394</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Yu L., Li M., Chen X., Tian Q., Jiang Y., Li N. MicroRNA-150 serves as a diagnostic biomarker and is involved in the inflammatory pathogenesis of Parkinson&#x2019;s disease. Mol. Genet. Genom. Med. 2020;8:e1189. doi: 10.1002/mgg3.1189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mgg3.1189</ArticleId><ArticleId IdType="pmc">PMC7196454</ArticleId><ArticleId IdType="pubmed">32077254</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin L.-X., Tan J.-Q., Zhang H.-N., Tang J.-G., Jiang B., Shen X.-M., Tang B.-S., Wang C.-Y. Preliminary study of hsa-miR-626 change in the cerebrospinal fluid of Parkinson&#x2019;s disease patients. J. Clin. Neurosci. 2019;70:198&#x2013;201. doi: 10.1016/j.jocn.2019.08.082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2019.08.082</ArticleId><ArticleId IdType="pubmed">31492481</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing R., Li L., Liu X., Tian B., Cheng Y. Down regulation of miR -218, miR -124, and miR -144 relates to Parkinson&#x2019;s disease via activating NF-&#x3ba;B signaling. Kaohsiung J. Med. Sci. 2020;36:786&#x2013;792. doi: 10.1002/kjm2.12241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/kjm2.12241</ArticleId><ArticleId IdType="pubmed">32492291</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazeli S., Motovali-Bashi M., Peymani M., Hashemi M.-S., Etemadifar M., Nasr-Esfahani M.H., Ghaedi K. A compound downregulation of SRRM2 and miR-27a-3p with upregulation of miR-27b-3p in PBMCs of Parkinson&#x2019;s patients is associated with the early stage onset of disease. PLoS ONE. 2020;15:e0240855. doi: 10.1371/journal.pone.0240855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240855</ArticleId><ArticleId IdType="pmc">PMC7654768</ArticleId><ArticleId IdType="pubmed">33171483</ArticleId></ArticleIdList></Reference><Reference><Citation>Gui Y., Liu H., Zhang L., Lv W., Hu X. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget. 2015;6:37043&#x2013;37053. doi: 10.18632/oncotarget.6158.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.6158</ArticleId><ArticleId IdType="pmc">PMC4741914</ArticleId><ArticleId IdType="pubmed">26497684</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Erviti L., Seow Y., Schapira A.H., Rodriguez-Oroz M.C., Obeso J.A., Cooper J.M. Influence of microRNA deregulation on chaperone-mediated autophagy and &#x3b1;-synuclein pathology in Parkinson&#x2019;s disease. Cell Death Dis. 2013;4:e545. doi: 10.1038/cddis.2013.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.73</ArticleId><ArticleId IdType="pmc">PMC3615743</ArticleId><ArticleId IdType="pubmed">23492776</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes A.J., Daniel S.E., Ben-Shlomo Y., Lees A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861&#x2013;870. doi: 10.1093/brain/awf080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awf080</ArticleId><ArticleId IdType="pubmed">11912118</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dijk K.D., Teunissen C.E., Drukarch B., Jimenez C.R., Groenewegen H.J., Berendse H.W., van de Berg W.D. Diagnostic cerebrospinal fluid biomarkers for Parkinson&#x2019;s disease: A pathogenetically based approach. Neurobiol. Dis. 2010;39:229&#x2013;241. doi: 10.1016/j.nbd.2010.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.04.020</ArticleId><ArticleId IdType="pmc">PMC7126274</ArticleId><ArticleId IdType="pubmed">20451609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mushtaq G., Greig N.H., Anwar F., Zamzami M.A., Choudhry H., Shaik M.M., Tamargo I.A., Kamal M.A. miRNAs as Circulating Biomarkers for Alzheimer&#x2019;s Disease and Parkinson&#x2019;s Disease. Med. Chem. 2016;12:217&#x2013;225. doi: 10.2174/1573406411666151030112140.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573406411666151030112140</ArticleId><ArticleId IdType="pmc">PMC6138249</ArticleId><ArticleId IdType="pubmed">26527155</ArticleId></ArticleIdList></Reference><Reference><Citation>Behbahanipour M., Peymani M., Salari M., Hashemi M.-S., Nasr-Esfahani M.H., Ghaedi K. Expression Profiling of Blood microRNAs 885, 361, and 17 in the Patients with the Parkinson&#x2019;s disease: Integrating Interaction Data to Uncover the Possible Triggering Age-Related Mechanisms. Sci. Rep. 2019;9:13759. doi: 10.1038/s41598-019-50256-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-50256-3</ArticleId><ArticleId IdType="pmc">PMC6760236</ArticleId><ArticleId IdType="pubmed">31551498</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossi I., Radeghieri A., Paolini L., Porrini V., Pilotto A., Padovani A., Marengoni A., Barbon A., Bellucci A., Pizzi M., et al. MicroRNA-34a-5p expression in the plasma and in its extracellular vesicle fractions in subjects with Parkinson&#x2019;s disease: An exploratory study. Int. J. Mol. Med. 2021;47:533&#x2013;546. doi: 10.3892/ijmm.2020.4806.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2020.4806</ArticleId><ArticleId IdType="pmc">PMC7797475</ArticleId><ArticleId IdType="pubmed">33416118</ArticleId></ArticleIdList></Reference><Reference><Citation>Cressatti M., Juwara L., Galindez J., Velly A.M., Nkurunziza E.S., Marier S., Canie O., Gornistky M., Schipper H.M. Salivary microR-153 and microR-223 Levels as Potential Diagnostic Biomarkers of Idiopathic Parkinson&#x2019;s Disease. Mov. Disord. 2020;35:468&#x2013;477. doi: 10.1002/mds.27935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27935</ArticleId><ArticleId IdType="pubmed">31800144</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie S., Niu W., Xu F., Wang Y., Hu S., Niu C. Differential expression and significance of miRNAs in plasma extracellular vesicles of patients with Parkinson&#x2019;s disease. Int. J. Neurosci. 2020:1&#x2013;16. doi: 10.1080/00207454.2020.1835899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00207454.2020.1835899</ArticleId><ArticleId IdType="pubmed">33045885</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahra W., Birla H., Singh S.S., Rathore A.S., Dilnashin H., Singh R., Keshri P.K., Gautam P., Singh S.P. Neuroprotection by Mucuna pruriens in Neurodegenerative Diseases. Neurochem. Res. 2022:1&#x2013;14. doi: 10.1007/s11064-022-03591-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-022-03591-3</ArticleId><ArticleId IdType="pubmed">35380400</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai S.N., Zahra W., Singh S.S., Birla H., Keswani C., Dilnashin H., Rathore A., Singh R., Singh R.K., Singh S. Anti-inflammatory Activity of Ursolic Acid in MPTP-Induced Parkinsonian Mouse Model. Neurotox. Res. 2019;36:452&#x2013;462. doi: 10.1007/s12640-019-00038-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-019-00038-6</ArticleId><ArticleId IdType="pubmed">31016688</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S.S., Rai S.N., Birla H., Zahra W., Kumar G., Gedda M.R., Tiwari N., Patnaik R., Singh R.K., Singh S. Effect of Chlorogenic Acid Supplementation in MPTP-Intoxicated Mouse. Front. Pharmacol. 2018;9:757. doi: 10.3389/fphar.2018.00757.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00757</ArticleId><ArticleId IdType="pmc">PMC6087758</ArticleId><ArticleId IdType="pubmed">30127737</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson R., Giovannoni G. Multiple sclerosis&#x2014;A review. Eur. J. Neurol. 2019;26:27&#x2013;40. doi: 10.1111/ene.13819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13819</ArticleId><ArticleId IdType="pubmed">30300457</ArticleId></ArticleIdList></Reference><Reference><Citation>Alroughani R., Yamout B.I. Multiple Sclerosis. Skull Base. 2018;38:212&#x2013;225. doi: 10.1055/s-0038-1649502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1649502</ArticleId><ArticleId IdType="pubmed">29791948</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsara M., Apostolopoulos V. Editorial: Multiple Sclerosis: Pathogenesis and Therapeutics. Med. Chem. 2018;14:104&#x2013;105. doi: 10.2174/157340641402180206092504.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157340641402180206092504</ArticleId><ArticleId IdType="pubmed">29453907</ArticleId></ArticleIdList></Reference><Reference><Citation>Dargahi N., Katsara M., Tselios T., Androutsou M.-E., De Courten M., Matsoukas J., Apostolopoulos V. Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sci. 2017;7:78. doi: 10.3390/brainsci7070078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci7070078</ArticleId><ArticleId IdType="pmc">PMC5532591</ArticleId><ArticleId IdType="pubmed">28686222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X., Zhou J., Zhong Y., Jiang L., Mu P., Li Y., Singh N., Nagarkatti M., Nagarkatti P. Expression, Regulation and Function of MicroRNAs in Multiple Sclerosis. Int. J. Med. Sci. 2014;11:810&#x2013;818. doi: 10.7150/ijms.8647.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.8647</ArticleId><ArticleId IdType="pmc">PMC4057480</ArticleId><ArticleId IdType="pubmed">24936144</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaguin M., Houlbert N., Fardel O., Lecureur V. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell. Immunol. 2013;281:51&#x2013;61. doi: 10.1016/j.cellimm.2013.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2013.01.010</ArticleId><ArticleId IdType="pubmed">23454681</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore C.S., Rao V.T., Msc B.A.D., Bedell B.J., Ludwin S.K., Bar-Or A., Antel J.P. miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization. Ann. Neurol. 2013;74:709&#x2013;720. doi: 10.1002/ana.23967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23967</ArticleId><ArticleId IdType="pubmed">23818336</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T., Lei Y., Jin S., Zhao Q., Cheng W., Xi Y., Wang L., Wang Z., Niu X., Chen G. miRNA-467b inhibits Th17 differentiation by targeting eIF4E in experimental autoimmune encephalomyelitis. Mol. Immunol. 2021;133:23&#x2013;33. doi: 10.1016/j.molimm.2021.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2021.02.008</ArticleId><ArticleId IdType="pubmed">33621940</ArticleId></ArticleIdList></Reference><Reference><Citation>Shademan B., Nourazarian A., Nikanfar M., Avci C.B., Hasanpour M., Isazadeh A. Investigation of the miRNA146a and miRNA155 gene expression levels in patients with multiple sclerosis. J. Clin. Neurosci. 2020;78:189&#x2013;193. doi: 10.1016/j.jocn.2020.04.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2020.04.071</ArticleId><ArticleId IdType="pubmed">32331943</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., He F., Pang R., Zhao D., Qiu W., Shan K., Zhang J., Lu Y., Li Y., Wang Y. Interleukin-17 (IL-17)-induced MicroRNA 873 (miR-873) Contributes to the Pathogenesis of Experimental Autoimmune Encephalomyelitis by Targeting A20 Ubiquitin-editing Enzyme. J. Biol. Chem. 2014;289:28971&#x2013;28986. doi: 10.1074/jbc.M114.577429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.577429</ArticleId><ArticleId IdType="pmc">PMC4200254</ArticleId><ArticleId IdType="pubmed">25183005</ArticleId></ArticleIdList></Reference><Reference><Citation>Pusic A.D., Kraig R.P. Youth and environmental enrichment generate serum exosomes containing miR-219 that promote CNS myelination. Glia. 2014;62:284&#x2013;299. doi: 10.1002/glia.22606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22606</ArticleId><ArticleId IdType="pmc">PMC4096126</ArticleId><ArticleId IdType="pubmed">24339157</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindberg R.L.P., Hoffmann F., Mehling M., Kuhle J., Kappos L. Altered expression of miR-17-5p in CD4+lymphocytes of relapsing-remitting multiple sclerosis patients. Eur. J. Immunol. 2010;40:888&#x2013;898. doi: 10.1002/eji.200940032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200940032</ArticleId><ArticleId IdType="pubmed">20148420</ArticleId></ArticleIdList></Reference><Reference><Citation>Marangon D., Boda E., Parolisi R., Negri C., Giorgi C., Montarolo F., Perga S., Bertolotto A., Buffo A., Abbracchio M.P., et al. In vivo silencing of miR-125a-3p promotes myelin repair in models of white matter demyelination. Glia. 2020;68:2001&#x2013;2014. doi: 10.1002/glia.23819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23819</ArticleId><ArticleId IdType="pubmed">32163190</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B., Ding Y., Li P., Wang T., He S., Jia Z., Yang J. MicroRNA-219c-5p regulates bladder fibrosis by targeting FN1. BMC Urol. 2020;20:193. doi: 10.1186/s12894-020-00765-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12894-020-00765-5</ArticleId><ArticleId IdType="pmc">PMC7720614</ArticleId><ArticleId IdType="pubmed">33287818</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Zhou D., Ren Y., Zhang Z., Guo X., Ma M., Xue Z., Lv J., Liu H., Xi Q., et al. Mir223 restrains autophagy and promotes CNS inflammation by targeting ATG16L1. Autophagy. 2019;15:478&#x2013;492. doi: 10.1080/15548627.2018.1522467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2018.1522467</ArticleId><ArticleId IdType="pmc">PMC6351131</ArticleId><ArticleId IdType="pubmed">30208760</ArticleId></ArticleIdList></Reference><Reference><Citation>Morquette B., Ju&#x17a;wik C.A., Drake S.S., Charabati M., Zhang Y., L&#xe9;cuyer M.-A., Galloway D.A., Dumas A., de Faria Junior O., Paradis-Isler N., et al. MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis. Brain. 2019;142:2979&#x2013;2995. doi: 10.1093/brain/awz245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz245</ArticleId><ArticleId IdType="pubmed">31412103</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimkhani S., Vafaee F., Young P.E., Hur S.S.J., Hawke S., Devenney E., Beadnall H., Barnett M.H., Suter C.M., Buckland M.E. Exosomal microRNA signatures in multiple sclerosis reflect disease status. Sci. Rep. 2017;7:14293. doi: 10.1038/s41598-017-14301-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-14301-3</ArticleId><ArticleId IdType="pmc">PMC5662562</ArticleId><ArticleId IdType="pubmed">29084979</ArticleId></ArticleIdList></Reference><Reference><Citation>Groen K., Maltby V.E., Scott R.J., Tajouri L., Lechner-Scott J. Erythrocyte microRNAs show biomarker potential and implicate multiple sclerosis susceptibility genes. Clin. Transl. Med. 2020;10:74&#x2013;90. doi: 10.1002/ctm2.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.22</ArticleId><ArticleId IdType="pmc">PMC7240864</ArticleId><ArticleId IdType="pubmed">32508012</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanoni M., Orlandi E., Rossetti G., Turatti M., Calabrese M., Lira M.G., Gajofatto A. Upregulated serum miR-128-3p in progressive and relapse-free multiple sclerosis patients. Acta Neurol. Scand. 2020;142:511&#x2013;516. doi: 10.1111/ane.13288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.13288</ArticleId><ArticleId IdType="pubmed">32432792</ArticleId></ArticleIdList></Reference><Reference><Citation>Vistbakka J., Sumelahti M.-L., Lehtim&#xe4;ki T., Elovaara I., Hagman S. Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients. Acta Neurol. Scand. 2018;138:130&#x2013;136. doi: 10.1111/ane.12921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12921</ArticleId><ArticleId IdType="pubmed">29527713</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghadam A.S.F., Ataei M., Arabzadeh G., Falahati K., Roshani F., Sanati M.H. Analysis of MicroRNA-18a Expression in Multiple Sclerosis Patients. Rep. Biochem. Mol. Biol. 2020;8:429&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7275836</ArticleId><ArticleId IdType="pubmed">32582802</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim S.H., El-Mehdawy K.M., Seleem M., El-Sawalhi M.M., Shaheen A.A. Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression. J. Neuroimmunol. 2020;347:577356. doi: 10.1016/j.jneuroim.2020.577356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2020.577356</ArticleId><ArticleId IdType="pubmed">32781341</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimirad S., Navaderi M., Alaei S., Sanati M.H. Identification of hsa-miR-106a-5p as an impact agent on promotion of multiple sclerosis using multi-step data analysis. Neurol. Sci. 2021;42:3791&#x2013;3799. doi: 10.1007/s10072-020-04979-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04979-1</ArticleId><ArticleId IdType="pubmed">33452935</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintana E., Ortega F.J., Robles-Cede&#xf1;o R., Villar M.L., Bux&#xf3; M., Mercader J.M., Alvarez-Cerme&#xf1;o J.C., Pueyo N., Perkal H., Fern&#xe1;ndez-Real J.M., et al. miRNAs in cerebrospinal fluid identify patients with MS and specifically those with lipid-specific oligoclonal IgM bands. Mult. Scler. J. 2017;23:1716&#x2013;1726. doi: 10.1177/1352458516684213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458516684213</ArticleId><ArticleId IdType="pubmed">28067602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandolesi G., Rizzo F., Balletta S., Bassi M.S., Gilio L., Guadalupi L., Nencini M., Moscatelli A., Ryan C., Licursi V., et al. The microRNA let-7b-5p Is Negatively Associated with Inflammation and Disease Severity in Multiple Sclerosis. Cells. 2021;10:330. doi: 10.3390/cells10020330.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020330</ArticleId><ArticleId IdType="pmc">PMC7915741</ArticleId><ArticleId IdType="pubmed">33562569</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Zhang Z.G., Lu M., Zhang Y., Shang X., Chopp M. MiR-146a promotes oligodendrocyte progenitor cell differentiation and enhances remyelination in a model of experimental autoimmune encephalomyelitis. Neurobiol. Dis. 2019;125:154&#x2013;162. doi: 10.1016/j.nbd.2019.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.01.019</ArticleId><ArticleId IdType="pubmed">30707940</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecca D., Marangon D., Coppolino G.T., M&#xe9;ndez A.M., Finardi A., Costa G.D., Martinelli V., Furlan R., Abbracchio M.P. MiR-125a-3p timely inhibits oligodendroglial maturation and is pathologically up-regulated in human multiple sclerosis. Sci. Rep. 2016;6:srep34503. doi: 10.1038/srep34503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep34503</ArticleId><ArticleId IdType="pmc">PMC5048305</ArticleId><ArticleId IdType="pubmed">27698367</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy C.P., McCoy C.E. The Role of MicroRNAs in Repair Processes in Multiple Sclerosis. Cells. 2020;9:1711. doi: 10.3390/cells9071711.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9071711</ArticleId><ArticleId IdType="pmc">PMC7408558</ArticleId><ArticleId IdType="pubmed">32708794</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel S.R., Mackenzie J., Chaplin G., Jablonski N.G., Griffiths L. Circulating microRNAs involved in multiple sclerosis. Mol. Biol. Rep. 2012;39:6219&#x2013;6225. doi: 10.1007/s11033-011-1441-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-011-1441-7</ArticleId><ArticleId IdType="pubmed">22231906</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;ndergaard H.B., Hesse D., Krakauer M., Sorensen P.S., Sellebjerg F. Differential microRNA expression in blood in multiple sclerosis. Mult. Scler. J. 2013;19:1849&#x2013;1857. doi: 10.1177/1352458513490542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458513490542</ArticleId><ArticleId IdType="pubmed">23773985</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller A., Leidinger P., Lange J., Borries A., Schroers H., Scheffler M., Lenhof H.-P., Ruprecht K., Meese E. Multiple Sclerosis: MicroRNA Expression Profiles Accurately Differentiate Patients with Relapsing-Remitting Disease from Healthy Controls. PLoS ONE. 2009;4:e7440. doi: 10.1371/journal.pone.0007440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0007440</ArticleId><ArticleId IdType="pmc">PMC2757919</ArticleId><ArticleId IdType="pubmed">19823682</ArticleId></ArticleIdList></Reference><Reference><Citation>Regev K., Paul A., Healy B., von Glenn F., Diaz-Cruz C., Gholipour T., Mazzola M.A., Raheja R., Nejad P., Glanz B.I., et al. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neurol.-Neuroimmunol. Neuroinflamm. 2016;3:e267. doi: 10.1212/NXI.0000000000000267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000267</ArticleId><ArticleId IdType="pmc">PMC4996540</ArticleId><ArticleId IdType="pubmed">27606352</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., Hernis A., Agostini S., Rovaris M., Caputo D., Clerici M. MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression. J. Transl. Med. 2015;13:148. doi: 10.1186/s12967-015-0504-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-015-0504-2</ArticleId><ArticleId IdType="pmc">PMC4429409</ArticleId><ArticleId IdType="pubmed">25947625</ArticleId></ArticleIdList></Reference><Reference><Citation>Honardoost M.A., Kiani-Esfahani A., Ghaedi K., Etemadifar M., Salehi M. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing&#x2013;remitting multiple sclerosis. Gene. 2014;544:128&#x2013;133. doi: 10.1016/j.gene.2014.04.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2014.04.069</ArticleId><ArticleId IdType="pubmed">24792898</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi S.J., Flower M., Ross C.A., Wild E.J. Huntington disease: New insights into molecular pathogenesis and therapeutic opportunities. Nat. Rev. Neurol. 2020;16:529&#x2013;546. doi: 10.1038/s41582-020-0389-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0389-4</ArticleId><ArticleId IdType="pubmed">32796930</ArticleId></ArticleIdList></Reference><Reference><Citation>McColgan P., Tabrizi S.J. Huntington&#x2019;s disease: A clinical review. Eur. J. Neurol. 2017;25:24&#x2013;34. doi: 10.1111/ene.13413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13413</ArticleId><ArticleId IdType="pubmed">28817209</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates G.P., Dorsey R., Gusella J.F., Hayden M.R., Kay C., Leavitt B.R., Nance M., Ross C.A., Scahill R.I., Wetzel R., et al. Huntington Disease. Nat. Rev. Dis. Primers. 2015;1:15005. doi: 10.1038/nrdp.2015.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2015.5</ArticleId><ArticleId IdType="pubmed">27188817</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulson H. Repeat expansion diseases. Neurovirology. 2018;147:105&#x2013;123. doi: 10.1016/b978-0-444-63233-3.00009-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-444-63233-3.00009-9</ArticleId><ArticleId IdType="pmc">PMC6485936</ArticleId><ArticleId IdType="pubmed">29325606</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans S., Douglas I., Rawlins M.D., Wexler N.S., Tabrizi S., Smeeth L. Prevalence of adult Huntington&#x2019;s disease in the UK based on diagnoses recorded in general practice records. J. Neurol. Neurosurg. Psychiatry. 2013;84:1156&#x2013;1160. doi: 10.1136/jnnp-2012-304636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304636</ArticleId><ArticleId IdType="pmc">PMC3786631</ArticleId><ArticleId IdType="pubmed">23482661</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross C.A., Aylward E.H., Wild E., Langbehn D., Long J., Warner J.H., Scahill R., Leavitt B.R., Stout J., Paulsen J., et al. Huntington disease: Natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 2014;10:204&#x2013;216. doi: 10.1038/nrneurol.2014.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.24</ArticleId><ArticleId IdType="pubmed">24614516</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X., Cong S. The Emerging Role of microRNAs in Polyglutamine Diseases. Front. Mol. Neurosci. 2019;12:156. doi: 10.3389/fnmol.2019.00156.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00156</ArticleId><ArticleId IdType="pmc">PMC6593396</ArticleId><ArticleId IdType="pubmed">31275113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang K.-H., Wu Y.-R., Chen C.-M. Down-regulation of miR-9* in the peripheral leukocytes of Huntington&#x2019;s disease patients. Orphanet J. Rare Dis. 2017;12:185. doi: 10.1186/s13023-017-0742-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-017-0742-x</ArticleId><ArticleId IdType="pmc">PMC5737985</ArticleId><ArticleId IdType="pubmed">29258536</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed; E., Pantano L., Ba&#xf1;ez-Coronel M., Llorens F., Mi&#xf1;ones-Moyano E., Porta S., Sumoy L., Ferrer I., Estivill X. A myriad of miRNA variants in control and Huntington&#x2019;s disease brain regions detected by massively parallel sequencing. Nucleic Acids Res. 2010;38:7219&#x2013;7235. doi: 10.1093/nar/gkq575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq575</ArticleId><ArticleId IdType="pmc">PMC2978354</ArticleId><ArticleId IdType="pubmed">20591823</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;ez-Planelles C., S&#xe1;nchez-Lozano P., Crespo M.D.C., Gil Zamorano J., Ribacoba R., Gonz&#xe1;lez N., Su&#xe1;rez E., Mart&#xed;nez-Descals A., Camblor P.M., &#xc1;lvarez V., et al. Circulating microRNAs in Huntington&#x2019;s disease: Emerging mediators in metabolic impairment. Pharmacol. Res. 2016;108:102&#x2013;110. doi: 10.1016/j.phrs.2016.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2016.05.005</ArticleId><ArticleId IdType="pubmed">27155059</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed E.R., Latourelle J.C., Bockholt J.H., Bregu J., Smock J., Paulsen J.S., Myers R.H. PREDICT-HD CSF ancillary study investigators MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study. Neurology. 2018;90:e264&#x2013;e272. doi: 10.1212/WNL.0000000000004844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004844</ArticleId><ArticleId IdType="pmc">PMC5798654</ArticleId><ArticleId IdType="pubmed">29282329</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M., Liu T., Im W., Mook-Jung I. MicroRNA-124 slows down the progression of Huntington&#x2032;s disease by promoting neurogenesis in the striatum. Neural Regen. Res. 2015;10:786&#x2013;791. doi: 10.4103/1673-5374.156978.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.156978</ArticleId><ArticleId IdType="pmc">PMC4468771</ArticleId><ArticleId IdType="pubmed">26109954</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P., Gao F., Wang N., Howland D., Kwak S., Vogt T.F., Aaronson J.S., Rosinski J., Coppola G., Horvath S., et al. MicroRNA signatures of endogenous Huntingtin CAG repeat expansion in mice. PLoS ONE. 2018;13:e0190550. doi: 10.1371/journal.pone.0190550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0190550</ArticleId><ArticleId IdType="pmc">PMC5764268</ArticleId><ArticleId IdType="pubmed">29324753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kocerha J., Xu Y., Prucha M.S., Zhao D., Chan A.W. microRNA-128a dysregulation in transgenic Huntington&#x2019;s disease monkeys. Mol. Brain. 2014;7:46. doi: 10.1186/1756-6606-7-46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-6606-7-46</ArticleId><ArticleId IdType="pmc">PMC4065582</ArticleId><ArticleId IdType="pubmed">24929669</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds R.H., Petersen M.H., Willert C.W., Heinrich M., Nymann N., Dall M., Treebak J.T., Bj&#xf6;rkqvist M., Silahtaroglu A., Hasholt L., et al. Perturbations in the p53/miR-34a/SIRT1 pathway in the R6/2 Huntington&#x2019;s disease model. Mol. Cell. Neurosci. 2018;88:118&#x2013;129. doi: 10.1016/j.mcn.2017.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2017.12.009</ArticleId><ArticleId IdType="pubmed">29289683</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.-T., Chu K., Im W.-S., Yoon H.-J., Im J.-Y., Park J.-E., Park K.-H., Jung K.-H., Lee S.K., Kim M., et al. Altered microRNA regulation in Huntington&#x2019;s disease models. Exp. Neurol. 2011;227:172&#x2013;179. doi: 10.1016/j.expneurol.2010.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2010.10.012</ArticleId><ArticleId IdType="pubmed">21035445</ArticleId></ArticleIdList></Reference><Reference><Citation>Her L.-S., Mao S.-H., Chang C.-Y., Cheng P.-H., Chang Y.-F., Yang H.-I., Chen C.-M., Yang S.-H. miR-196a Enhances Neuronal Morphology through Suppressing RANBP10 to Provide Neuroprotection in Huntington&#x2019;s Disease. Theranostics. 2017;7:2452&#x2013;2462. doi: 10.7150/thno.18813.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.18813</ArticleId><ArticleId IdType="pmc">PMC5525749</ArticleId><ArticleId IdType="pubmed">28744327</ArticleId></ArticleIdList></Reference><Reference><Citation>Peplow P.V., Martinez B. Altered microRNA expression in animal models of Huntington&#x2019;s disease and potential therapeutic strategies. Neural Regen. Res. 2021;16:2159&#x2013;2169. doi: 10.4103/1673-5374.310673.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.310673</ArticleId><ArticleId IdType="pmc">PMC8354140</ArticleId><ArticleId IdType="pubmed">33818488</ArticleId></ArticleIdList></Reference><Reference><Citation>Vezzoli E., Caron I., Talpo F., Besusso D., Conforti P., Battaglia E., Sogne E., Falqui A., Petricca L., Verani M., et al. Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington&#x2019;s disease. J. Clin. Investig. 2019;129:2390&#x2013;2403. doi: 10.1172/JCI120616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI120616</ArticleId><ArticleId IdType="pmc">PMC6546448</ArticleId><ArticleId IdType="pubmed">31063986</ArticleId></ArticleIdList></Reference><Reference><Citation>Das E., Jana N.R., Bhattacharyya N.P. MicroRNA-124 targets CCNA2 and regulates cell cycle in STHdh/Hdh cells. Biochem. Biophys. Res. Commun. 2013;437:217&#x2013;224. doi: 10.1016/j.bbrc.2013.06.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2013.06.041</ArticleId><ArticleId IdType="pubmed">23796713</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.-T., Im W., Ban J.-J., Lee M., Jung K.-H., Lee S.K., Chu K., Kim M. Exosome-Based Delivery of miR-124 in a Huntington&#x2019;s Disease Model. J. Mov. Disord. 2017;10:45&#x2013;52. doi: 10.14802/jmd.16054.</Citation><ArticleIdList><ArticleId IdType="doi">10.14802/jmd.16054</ArticleId><ArticleId IdType="pmc">PMC5288667</ArticleId><ArticleId IdType="pubmed">28122430</ArticleId></ArticleIdList></Reference><Reference><Citation>Caron N.S., Southwell A.L., Brouwers C.C., Cengio L.D., Xie Y., Black H.F., Anderson L.M., Ko S., Zhu X., Van Deventer S.J., et al. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Res. 2020;48:36&#x2013;54. doi: 10.1093/nar/gkz976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz976</ArticleId><ArticleId IdType="pmc">PMC7145682</ArticleId><ArticleId IdType="pubmed">31745548</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfister E.L., DiNardo N., Mondo E., Borel F., Conroy F., Fraser C., Gernoux G., Han X., Hu D., Johnson E., et al. Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington&#x2019;s Disease. Hum. Gene Ther. 2018;29:663&#x2013;673. doi: 10.1089/hum.2017.199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2017.199</ArticleId><ArticleId IdType="pmc">PMC6909722</ArticleId><ArticleId IdType="pubmed">29207890</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur K.C., Calvo A., Price T.R., Geiger J.T., Chi&#xf2; A., Traynor B.J. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat. Commun. 2016;7:12408. doi: 10.1038/ncomms12408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragagnin A.M.G., Shadfar S., Vidal M., Jamali S., Atkin J.D. Motor Neuron Susceptibility in ALS/FTD. Front. Neurosci. 2019;13:532. doi: 10.3389/fnins.2019.00532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00532</ArticleId><ArticleId IdType="pmc">PMC6610326</ArticleId><ArticleId IdType="pubmed">31316328</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Al-Chalabi A., Chio A., Hardiman O., Kiernan M.C., Rohrer J., Rowe J., Seeley W., Talbot K. Genetic screening in sporadic ALS and FTD. J. Neurol. Neurosurg. Psychiatry. 2017;88:1042&#x2013;1044. doi: 10.1136/jnnp-2017-315995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315995</ArticleId><ArticleId IdType="pmc">PMC5740553</ArticleId><ArticleId IdType="pubmed">28642287</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar U.G., Milla V., Cynthia Stafford M.Y., Bjourson A.J., Duddy W., Duguez S.M.-R. A Systematic Review of Suggested Molecular Strata, Biomarkers and Their Tissue Sources in ALS. Front. Neurol. 2019;10:400. doi: 10.3389/fneur.2019.00400.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00400</ArticleId><ArticleId IdType="pmc">PMC6527847</ArticleId><ArticleId IdType="pubmed">31139131</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk A.E., Weishaupt J.H., Andersen P.M., Ludolph A.C., Kubisch C. Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Med. Genet. 2018;30:252&#x2013;258. doi: 10.1007/s11825-018-0185-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11825-018-0185-3</ArticleId><ArticleId IdType="pmc">PMC6132774</ArticleId><ArticleId IdType="pubmed">30220791</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R., Chi&#xf2; A., Traynor B.J. Novel genes associated with amyotrophic lateral sclerosis: Diagnostic and clinical implications. Lancet Neurol. 2018;17:94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebasti&#xe3;o A.M., Rei N., Ribeiro J.A. Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors. Front. Pharmacol. 2018;9:267. doi: 10.3389/fphar.2018.00267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00267</ArticleId><ArticleId IdType="pmc">PMC5911503</ArticleId><ArticleId IdType="pubmed">29713276</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H., Jr., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilmaghani N.A., Hussen B.M., Nateghinia S., Taheri M., Ghafouri-Fard S. Emerging role of microRNAs in the pathogenesis of amyotrophic lateral sclerosis. Metab. Brain Dis. 2021;36:737&#x2013;749. doi: 10.1007/s11011-021-00697-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-021-00697-5</ArticleId><ArticleId IdType="pubmed">33604874</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luna N., Turon-Sans J., Cortes-Vicente E., Carrasco-Rozas A., Ill&#xe1;n-Gala I., Dols-Icardo O., Clarim&#xf3;n J., Lle&#xf3; A., Gallardo E., Illa I., et al. Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. Sci. Rep. 2020;10:4348. doi: 10.1038/s41598-020-61246-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-61246-1</ArticleId><ArticleId IdType="pmc">PMC7062873</ArticleId><ArticleId IdType="pubmed">32152380</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Chen Y., Chen X., Wei Q., Ou R., Gu X., Cao B., Shang H. MicroRNA-183-5p is stress-inducible and protects neurons against cell death in amyotrophic lateral sclerosis. J. Cell. Mol. Med. 2020;24:8614&#x2013;8622. doi: 10.1111/jcmm.15490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15490</ArticleId><ArticleId IdType="pmc">PMC7412410</ArticleId><ArticleId IdType="pubmed">32558113</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichenstein I., Eitan C., Diaz-Garcia S., Haim G., Magen I., Siany A., Hoye M.L., Rivkin N., Olender T., Toth B., et al. Human genetics and neuropathology suggest a link between miR-218 and amyotrophic lateral sclerosis pathophysiology. Sci. Transl. Med. 2019;11:eaav5264. doi: 10.1126/scitranslmed.aav5264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aav5264</ArticleId><ArticleId IdType="pmc">PMC7057809</ArticleId><ArticleId IdType="pubmed">31852800</ArticleId></ArticleIdList></Reference><Reference><Citation>Loffreda A., Nizzardo M., Arosio A., Ruepp M.-D., Calogero R., Volinia S., Galasso M., Bendotti C., Ferrarese C., Lunetta C., et al. miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis. Prog. Neurobiol. 2020;190:101803. doi: 10.1016/j.pneurobio.2020.101803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2020.101803</ArticleId><ArticleId IdType="pubmed">32335272</ArticleId></ArticleIdList></Reference><Reference><Citation>Matamala J.M., Arias-Carrasco R., Sanchez C., Uhrig M., Bargsted L., Matus S., Maracaja-Coutinho V., Abarzua S., van Zundert B., Verdugo R., et al. Genome-wide circulating microRNA expression profiling reveals potential biomarkers for amyotrophic lateral sclerosis. Neurobiol. Aging. 2018;64:123&#x2013;138. doi: 10.1016/j.neurobiolaging.2017.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.12.020</ArticleId><ArticleId IdType="pubmed">29458840</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurita H., Yabe S., Ueda T., Inden M., Kakita A., Hozumi I. MicroRNA-5572 Is a Novel MicroRNA-Regulating SLC30A3 in Sporadic Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2020;21:4482. doi: 10.3390/ijms21124482.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21124482</ArticleId><ArticleId IdType="pmc">PMC7350020</ArticleId><ArticleId IdType="pubmed">32599739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kmetzsch V., Anquetil V., Saracino D., Rinaldi D., Camuzat A., Gareau T., Jornea L., Forlani S., Couratier P., Wallon D., et al. Plasma microRNA signature in presymptomatic and symptomatic subjects with C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2021;92:485&#x2013;493. doi: 10.1136/jnnp-2020-324647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-324647</ArticleId><ArticleId IdType="pmc">PMC8053348</ArticleId><ArticleId IdType="pubmed">33239440</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Martone J., Lepore E., Casola I., Petrucci A., Inghilleri M., Morlando M., Colantoni A., Scicchitano B.M., Calvo A., et al. A longitudinal study defined circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients. Cell Death Discov. 2021;7:4. doi: 10.1038/s41420-020-00397-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-020-00397-6</ArticleId><ArticleId IdType="pmc">PMC7801652</ArticleId><ArticleId IdType="pubmed">33431881</ArticleId></ArticleIdList></Reference><Reference><Citation>Arakawa Y., Itoh S., Fukazawa Y., Ishiguchi H., Kohmoto J., Hironishi M., Ito H., Kihira T. Association between oxidative stress and microRNA expression pattern of ALS patients in the high-incidence area of the Kii Peninsula. Brain Res. 2020;1746:147035. doi: 10.1016/j.brainres.2020.147035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2020.147035</ArticleId><ArticleId IdType="pubmed">32739158</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovanda A., Leonardis L., Zidar J., Koritnik B., Dolenc-Groselj L., Kovacic S.R., Curk T., Rogelj B. Differential expression of microRNAs and other small RNAs in muscle tissue of patients with ALS and healthy age-matched controls. Sci. Rep. 2018;8:5609. doi: 10.1038/s41598-018-23139-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-23139-2</ArticleId><ArticleId IdType="pmc">PMC5884852</ArticleId><ArticleId IdType="pubmed">29618798</ArticleId></ArticleIdList></Reference><Reference><Citation>Benigni M., Ricci C., Jones A.R., Giannini F., Al-Chalabi A., Battistini S. Identification of miRNAs as Potential Biomarkers in Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients. NeuroMol. Med. 2016;18:551&#x2013;560. doi: 10.1007/s12017-016-8396-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-016-8396-8</ArticleId><ArticleId IdType="pubmed">27119371</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Zhang L. MicroRNAs in amyotrophic lateral sclerosis: From pathogenetic involvement to diagnostic biomarker and therapeutic agent development. Neurol. Sci. 2020;41:3569&#x2013;3577. doi: 10.1007/s10072-020-04773-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04773-z</ArticleId><ArticleId IdType="pubmed">33006054</ArticleId></ArticleIdList></Reference><Reference><Citation>Banack S.A., Dunlop R.A., Cox P.A. An miRNA fingerprint using neural-enriched extracellular vesicles from blood plasma: Towards a biomarker for amyotrophic lateral sclerosis/motor neuron disease. Open Biol. 2020;10:200116. doi: 10.1098/rsob.200116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.200116</ArticleId><ArticleId IdType="pmc">PMC7333885</ArticleId><ArticleId IdType="pubmed">32574550</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelick J., Men Y., Jin S., Seo S., Espejo-Porras F., Yang Y. Elevated exosomal secretion of miR-124-3p from spinal neurons positively associates with disease severity in ALS. Exp. Neurol. 2020;333:113414. doi: 10.1016/j.expneurol.2020.113414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2020.113414</ArticleId><ArticleId IdType="pmc">PMC7502520</ArticleId><ArticleId IdType="pubmed">32712030</ArticleId></ArticleIdList></Reference><Reference><Citation>Si Y., Cui X., Crossman D.K., Hao J., Kazamel M., Kwon Y., King P.H. Muscle microRNA signatures as biomarkers of disease progression in amyotrophic lateral sclerosis. Neurobiol. Dis. 2018;114:85&#x2013;94. doi: 10.1016/j.nbd.2018.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.02.009</ArticleId><ArticleId IdType="pmc">PMC5891369</ArticleId><ArticleId IdType="pubmed">29486297</ArticleId></ArticleIdList></Reference><Reference><Citation>Varcianna A., Myszczynska M.A., Castelli L.M., O&#x2019;Neill B., Kim Y., Talbot J., Nyberg S., Nyamali I., Heath P.R., Stopford M.J., et al. Micro-RNAs secreted through astrocyte-derived extracellular vesicles cause neuronal network degeneration in C9orf72 ALS. EBioMedicine. 2019;40:626&#x2013;635. doi: 10.1016/j.ebiom.2018.11.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.11.067</ArticleId><ArticleId IdType="pmc">PMC6413467</ArticleId><ArticleId IdType="pubmed">30711519</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R., Liefhebber J.M., Miniarikova J., van der Zon T., Snapper J., Kolder I., Petry H., van Deventer S.J., Evers M.M., Konstantinova P. Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol. Ther.-Nucleic Acids. 2019;14:593&#x2013;608. doi: 10.1016/j.omtn.2019.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.01.010</ArticleId><ArticleId IdType="pmc">PMC6378669</ArticleId><ArticleId IdType="pubmed">30776581</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung Y.-T., Peng K.-C., Chen Y.-C., Yen Y.-P., Chang M., Thams S., Chen J.-A. Mir-17~92 Confers Motor Neuron Subtype Differential Resistance to ALS-Associated Degeneration. Cell Stem Cell. 2019;25:193&#x2013;209.e7. doi: 10.1016/j.stem.2019.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2019.04.016</ArticleId><ArticleId IdType="pubmed">31155482</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O., Jedrychowski M.P., Cialic R., Krasemann S., Murugaiyan G., Fanek Z., Greco D.J., Wu P.M., Doykan C.E., Kiner O., et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann. Neurol. 2015;77:75&#x2013;99. doi: 10.1002/ana.24304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24304</ArticleId><ArticleId IdType="pmc">PMC4432483</ArticleId><ArticleId IdType="pubmed">25381879</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan K., Mitchem M.R., Jimenez-Mateos E.M., Henshall D.C., Concannon C.G., Prehn J.H.M. Increased Expression of MicroRNA-29a in ALS Mice: Functional Analysis of Its Inhibition. J. Mol. Neurosci. 2014;53:231&#x2013;241. doi: 10.1007/s12031-014-0290-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-014-0290-y</ArticleId><ArticleId IdType="pubmed">24696165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju&#x17a;wik C.A., Drake S.S., Zhang Y., Paradis-Isler N., Sylvester A., Amar-Zifkin A., Douglas C., Morquette B., Moore C.S., Fournier A.E. microRNA dysregulation in neurodegenerative diseases: A systematic review. Prog. Neurobiol. 2019;182:101664. doi: 10.1016/j.pneurobio.2019.101664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2019.101664</ArticleId><ArticleId IdType="pubmed">31356849</ArticleId></ArticleIdList></Reference><Reference><Citation>Konovalova J., Gerasymchuk D., Parkkinen I., Chmielarz P., Domanskyi A. Interplay between MicroRNAs and Oxidative Stress in Neurodegenerative Diseases. Int. J. Mol. Sci. 2019;20:6055. doi: 10.3390/ijms20236055.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20236055</ArticleId><ArticleId IdType="pmc">PMC6929013</ArticleId><ArticleId IdType="pubmed">31801298</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahimi F., Maira M., Barcelona P., Galan A., Aboulkassim T., Teske K., Rogers M.-L., Bertram L., Wang J., Yousefi M., et al. The Paradoxical Signals of Two TrkC Receptor Isoforms Supports a Rationale for Novel Therapeutic Strategies in ALS. PLoS ONE. 2016;11:e0162307. doi: 10.1371/journal.pone.0162307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0162307</ArticleId><ArticleId IdType="pmc">PMC5047590</ArticleId><ArticleId IdType="pubmed">27695040</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerau-De-Arellano M., Smith K.M., Godlewski J., Liu Y., Winger R., Lawler S.E., Whitacre C.C., Racke M.K., Lovett-Racke A.E. Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain. 2011;134:3578&#x2013;3589. doi: 10.1093/brain/awr262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr262</ArticleId><ArticleId IdType="pmc">PMC3235556</ArticleId><ArticleId IdType="pubmed">22088562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye M., Chen Y., Xie J., Yu M., Shi P., Xu W., Gui Z., Liu X. miRNA-140-5p Play an Important Role of Parkinson&#x2019;s Disease Development. J. Biomater. Tissue Eng. 2018;8:1566&#x2013;1572. doi: 10.1166/jbt.2018.1905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1166/jbt.2018.1905</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R., Li Y., Zhou H., Wang H., Liu D., Wang H., Wang Z. WITHDRAWN: OIP5-AS1 facilitates Th17 differentiation and EAE severity by targeting miR-140-5p to regulate RhoA/ROCK2 signaling pathway. Life Sci. 2021:119108. doi: 10.1016/j.lfs.2021.119108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2021.119108</ArticleId><ArticleId IdType="pubmed">33515560</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S., Zhang X., Guan H., Huang F., Wu L., Hou D., Zheng Z., Yu M., Huang L., Ge L. miR-140-5p regulates T cell differentiation and attenuates experimental autoimmune encephalomyelitis by affecting CD4+T cell metabolism and DNA methylation. Int. Immunopharmacol. 2019;75:105778. doi: 10.1016/j.intimp.2019.105778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2019.105778</ArticleId><ArticleId IdType="pubmed">31494340</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie B., Liu Z., Jiang L., Liu W., Song M., Zhang Q., Zhang R., Cui D., Wang X., Xu S. Increased Serum miR-206 Level Predicts Conversion from Amnestic Mild Cognitive Impairment to Alzheimer&#x2019;s Disease: A 5-Year Follow-up Study. J. Alzheimer&#x2019;s Dis. 2017;55:509&#x2013;520. doi: 10.3233/JAD-160468.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160468</ArticleId><ArticleId IdType="pubmed">27662297</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Zhang Y., Zhang L., Dong Y., Ji H., Shen L. The Potential Markers of Circulating microRNAs and long non-coding RNAs in Alzheimer&#x2019;s Disease. Aging Dis. 2019;10:1293&#x2013;1301. doi: 10.14336/AD.2018.1105.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2018.1105</ArticleId><ArticleId IdType="pmc">PMC6844586</ArticleId><ArticleId IdType="pubmed">31788340</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.-N., Wang Y.-J., Wang H., Song L., Chen Y., Wang J.-L., Ye Y., Jiang B. The Anti-dementia Effects of Donepezil Involve miR-206-3p in the Hippocampus and Cortex. Biol. Pharm. Bull. 2017;40:465&#x2013;472. doi: 10.1248/bpb.b16-00898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.b16-00898</ArticleId><ArticleId IdType="pubmed">28123152</ArticleId></ArticleIdList></Reference><Reference><Citation>Aloi M.S., Prater K.E., Sopher B., Davidson S., Jayadev S., Garden G.A. The pro-inflammatory microRNA miR-155 influences fibrillar &#x3b2;-Amyloid 1-42 catabolism by microglia. Glia. 2021;69:1736&#x2013;1748. doi: 10.1002/glia.23988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23988</ArticleId><ArticleId IdType="pmc">PMC9098129</ArticleId><ArticleId IdType="pubmed">33694209</ArticleId></ArticleIdList></Reference><Reference><Citation>Readhead B., Haure-Mirande J.-V., Mastroeni D., Audrain M., Fanutza T., Kim S.H., Blitzer R.D., Gandy S., Dudley J.T., Ehrlich M.E. miR155 regulation of behavior, neuropathology, and cortical transcriptomics in Alzheimer&#x2019;s disease. Acta Neuropathol. 2020;140:295&#x2013;315. doi: 10.1007/s00401-020-02185-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02185-z</ArticleId><ArticleId IdType="pmc">PMC8414561</ArticleId><ArticleId IdType="pubmed">32666270</ArticleId></ArticleIdList></Reference><Reference><Citation>Miniarikova J., Zimmer V., Martier R., Brouwers C.C., Pythoud C., Richetin K., Rey M., Lubelski J., Evers M., Van Deventer S.J., et al. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington&#x2019;s disease. Gene Ther. 2017;24:630&#x2013;639. doi: 10.1038/gt.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2017.71</ArticleId><ArticleId IdType="pmc">PMC5658675</ArticleId><ArticleId IdType="pubmed">28771234</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha C., Santos C., Gomes C., Fernandes A., Correia A.M., Sebasti&#xe3;o A.M., Vaz A.R., Brites D. Downregulated Glia Interplay and Increased miRNA-155 as Promising Markers to Track ALS at an Early Stage. Mol. Neurobiol. 2018;5:4207&#x2013;4224. doi: 10.1007/s12035-017-0631-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0631-2</ArticleId><ArticleId IdType="pubmed">28612258</ArticleId></ArticleIdList></Reference><Reference><Citation>Thome A.D., Harms A.S., Volpicelli-Daley L.A., Standaert D.G. microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease. J. Neurosci. 2016;36:2383&#x2013;2390. doi: 10.1523/JNEUROSCI.3900-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3900-15.2016</ArticleId><ArticleId IdType="pmc">PMC4764660</ArticleId><ArticleId IdType="pubmed">26911687</ArticleId></ArticleIdList></Reference><Reference><Citation>Caggiu E., Paulus K., Mameli G., Arru G., Sechi G.P., Sechi L.A. Differential expression of miRNA 155 and miRNA 146a in Parkinson&#x2019;s disease patients. eNeurologicalSci. 2018;13:1&#x2013;4. doi: 10.1016/j.ensci.2018.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2018.09.002</ArticleId><ArticleId IdType="pmc">PMC6149197</ArticleId><ArticleId IdType="pubmed">30255159</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazloumfard F., Mirian M., Eftekhari S.-M., Aliomrani M. Hydroxychloroquine effects on miR-155-3p and miR-219 expression changes in animal model of multiple sclerosis. Metab. Brain Dis. 2020;35:1299&#x2013;1307. doi: 10.1007/s11011-020-00609-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-020-00609-z</ArticleId><ArticleId IdType="pubmed">32860610</ArticleId></ArticleIdList></Reference><Reference><Citation>He B., Chen W., Zeng J., Tong W., Zheng P. MicroRNA-326 decreases tau phosphorylation and neuron apoptosis through inhibition of the JNK signaling pathway by targeting VAV1 in Alzheimer&#x2019;s disease. J. Cell. Physiol. 2020;235:480&#x2013;493. doi: 10.1002/jcp.28988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.28988</ArticleId><ArticleId IdType="pubmed">31385301</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu R., Liu R., Wang L., Tang M., Li S.-R., Hu X. LncRNA RPPH1 attenuates A&#x3b2;25-35-induced endoplasmic reticulum stress and apoptosis in SH-SY5Y cells via miR-326/PKM2. Int. J. Neurosci. 2020;131:425&#x2013;432. doi: 10.1080/00207454.2020.1746307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00207454.2020.1746307</ArticleId><ArticleId IdType="pubmed">32336203</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice B., Manfellotto F., Fiorentino G., Annunziata A., Biffali E., Pannone R., Federico A. Wide-Ranging Analysis of MicroRNA Profiles in Sporadic Amyotrophic Lateral Sclerosis Using Next-Generation Sequencing. Front. Genet. 2018;9:310. doi: 10.3389/fgene.2018.00310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2018.00310</ArticleId><ArticleId IdType="pmc">PMC6102490</ArticleId><ArticleId IdType="pubmed">30154826</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Xu W., Nan S., Chang M., Fan J. MicroRNA-326 Inhibits Apoptosis and Promotes Proliferation of Dopaminergic Neurons in Parkinson&#x2019;s Disease Through Suppression of KLK7-Mediated MAPK Signaling Pathway. J. Mol. Neurosci. 2019;69:197&#x2013;214. doi: 10.1007/s12031-019-01349-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-019-01349-1</ArticleId><ArticleId IdType="pubmed">31270675</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Wang Y., Yang J., Liu H., Wang L. MicroRNA-326 suppresses iNOS expression and promotes autophagy of dopaminergic neurons through the JNK signaling by targeting XBP1 in a mouse model of Parkinson&#x2019;s disease. J. Cell. Biochem. 2019;120:14995&#x2013;15006. doi: 10.1002/jcb.28761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.28761</ArticleId><ArticleId IdType="pubmed">31135066</ArticleId></ArticleIdList></Reference><Reference><Citation>Azimi M., Ghabaee M., Moghadasi A.N., Izad M. Altered Expression of miR-326 in T Cell-derived Exosomes of Patients with Relapsing-remitting Multiple Sclerosis. Iran. J. Allergy Asthma Immunol. 2019;18:108&#x2013;113. doi: 10.18502/ijaai.v18i1.636.</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/ijaai.v18i1.636</ArticleId><ArticleId IdType="pubmed">30848579</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng M., Zhang Q., Wu Z., Ma T., He A., Zhang T., Ke X., Yu Q., Han Y., Lu Y. Mossy cell synaptic dysfunction causes memory imprecision via miR-128 inhibition of STIM2 in Alzheimer&#x2019;s disease mouse model. Aging Cell. 2020;19:e13144. doi: 10.1111/acel.13144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13144</ArticleId><ArticleId IdType="pmc">PMC7253057</ArticleId><ArticleId IdType="pubmed">32222058</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehfeld F., Maticzka D., Grosser S., Knauff P., Eravci M., Vida I., Backofen R., Wulczyn F.G. The RNA-binding protein ARPP21 controls dendritic branching by functionally opposing the miRNA it hosts. Nat. Commun. 2018;9:1235. doi: 10.1038/s41467-018-03681-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03681-3</ArticleId><ArticleId IdType="pmc">PMC5964322</ArticleId><ArticleId IdType="pubmed">29581509</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori M., Nuzziello N., Introna A., Consiglio A., Licciulli F., D&#x2019;Errico E., Scarafino A., Distaso E., Simone I.L. Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients with Sporadic Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2018;11:288. doi: 10.3389/fnmol.2018.00288.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00288</ArticleId><ArticleId IdType="pmc">PMC6121079</ArticleId><ArticleId IdType="pubmed">30210287</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L., Yang L., Li Y.-J., Mei R., Yu H.-L., Gong Y., Du M.-Y., Wang F. MicroRNA-128 Protects Dopamine Neurons from Apoptosis and Upregulates the Expression of Excitatory Amino Acid Transporter 4 in Parkinson&#x2019;s Disease by Binding to AXIN1. Cell. Physiol. Biochem. 2018;51:2275&#x2013;2289. doi: 10.1159/000495872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000495872</ArticleId><ArticleId IdType="pubmed">30537735</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhter R., Shao Y., Shaw M., Formica S., Khrestian M., Leverenz J.B., Bekris L.M. Regulation of ADAM10 by miR-140-5p and potential relevance for Alzheimer&#x2019;s disease. Neurobiol. Aging. 2018;63:110&#x2013;119. doi: 10.1016/j.neurobiolaging.2017.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.11.007</ArticleId><ArticleId IdType="pmc">PMC5800962</ArticleId><ArticleId IdType="pubmed">29253717</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang C., Mu Y., Tian H., Wang D., Zhang S., Wang H., Liu Y., Di C. MicroRNA-140 silencing represses the incidence of Alzheimer&#x2019;s disease. Neurosci. Lett. 2021;758:135674. doi: 10.1016/j.neulet.2021.135674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2021.135674</ArticleId><ArticleId IdType="pubmed">33529652</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R., Goodall E., Milo M., Cooper-Knock J., Da Costa M., Hobson E., Kazoka M., Wollff H., Heath P.R., Shaw P., et al. Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS) Neurobiol. Aging. 2017;55:123&#x2013;131. doi: 10.1016/j.neurobiolaging.2017.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.03.027</ArticleId><ArticleId IdType="pmc">PMC5455071</ArticleId><ArticleId IdType="pubmed">28454844</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>